CURRICULUM VITAE
David George Beer, Ph.D.
Professor
6304 Cancer Center
734-763-0325
dgbeer@umich.edu
EDUCATION AND TRAINING
1971-1975
Northeastern Illinois University, Chicago, IL., B.S. with Honors.
1980-1984
University of Colorado, Boulder, CO., Ph.D.
(Biochemical Pharmacology, Mentor: Alvin Malkinson,
1984-1986
Individual National Research Service Award, NIH,
McArdle Laboratory for Cancer Research, Madison, WI.
(Molecular Oncology, Mentor: Henry Pitot, M.D., Ph.D.)
Ph.D.)
ACADEMIC APPOINTMENTS
1987-1991
Assistant Professor, Department of Pharmacology, Toxicology
and Therapeutics, Center on Environmental and
Occupational
Health, University of Kansas
Medical Center. Member,
Graduate Faculty.
1991
Assistant Professor, Departments of Surgery and Radiation
Oncology, University of Michigan, Ann Arbor MI.
1991
Member, University of Michigan Comprehensive
Cancer Center. Member of Cancer Genetics, Chemoprevention and
Thoracic Oncology Programs
1991
Member, Cancer Biology Group, Department of Radiation
Oncology.
1994
Associate Professor, Departments of Surgery and Radiation Oncology,
Director, Thoracic Research Laboratory, University of
Michigan, Ann
Arbor MI.
2001
David G. Beer, Ph.D.
Professor, Department of Surgery and Department of Radiation
Oncology, Director, Thoracic Research Laboratory, University of
Michigan, Ann Arbor MI.
2/9/16
1
2003
Co-Director, Cancer Genetics Program, University of Michigan Cancer
Center
2004
Cores Advisory Committee, University of Michigan Cancer Center
2007
2008
Arbor MI
John A. and Carla S. Klein Professor in Thoracic Surgery
Co-founder: Armune Biosciences with Arul Chinniayan, Ann
GRANTS
Current:
Cancer Center Support Grant
Cancer Genetics Program, Co-director (5% effort)
5 P30 CA46592-25
Period: 6/01/12 - 5/31/17
The core grant supports the senior leadership, programs and shared facilities of the
Cancer Center. The Center provides the organizational framework to promote
interdisciplinary research through the development of defined clinical, basic science and
prevention programs in cancer research, and the development and support of shared
resources.
Annual directs: $5,311,806
Identification and Characterization of Gene Fusions in Lung Adenocarcinoma
Principal Investigators: David G. Beer (22.8% effort), Arul Chinnaiyan
Agency: National Cancer Institute
Period: 4/01/2011 – 3/30/2016
This R01 proposal will identify new gene-fusions in lung cancer utilizing a newly
developed bioinformatics approach combined with next-generation sequencing data.
$185,000 direct costs/yr.
RFA-CA-10-014: Barrett’s Esophagus Translational Research Network (U54)
Multi-Spectral Targeted Imaging for Early Detection of Cancer in Barrett's Esophagus
Principal Investigators: Tom Wang, David G. Beer (22% effort), Eric Siebel
Period: 09/21/2011-8/31/2016
$830,151 annual direct costs
NIH Strategic Partnering to Evaluate Cancer Signatures [SPECS II] (U01); PAR-10-126
Prognostic Signature Validation in Lung Squamous Cell Carcinomas
Principal Investigator: Fred Hirsch, M.D., Ph.D.
Co-Investigator, David G. Beer, (5% effort)
Co-Investigators: Guoan Chen, (25% effort)
3/01/12 – 2/29/17
$70,148 total annual costs MI
UMCCC-Endowed Research Fund
Esophageal Cancer Xenografts
David G. Beer, Ph.D.
2/9/16
2
Period: 5/1/2011Principal Investigator: David G. Beer, Ph.D.
Co-Investigators: Andrew Chang, Jules Lin, Rishi Reddy, Lin Lin
$50,000 total costs.
Submitted:
Standardized NanoArray PCR for Gene Expression Profiling of
Lung Cancer
PA-11-096 PHS 2011-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for
Small Business Innovation Research Grant
Principle Investigators: Tony Godfrey, Tom Morrison, David G. Beer
$116,802 direct costs
Previous:
A Novel Computational Framework for Individualized Clinical Decision Making
Principal Investigator: Lan Guo, West Virginia University
(David G. Beer, Co-Investigator)(10% effort)
Agency: National Cancer Institute
Period: 9/15/08 – 9/14/11
$21,089 total costs
Assessment of DNA Copy Number Alterations with Lung Adenocarcinoma Prognosis.
DOD NFGC
Period: 6/01/10 – 5/30/11
Principal Investigator: David G. Beer, Ph.D., 1% effort
Co-Investigators: Guoan Chen
$100,000 total costs.
Serum miRNAs in Lung Cancer Diagnosis and Prognosis
UMCCC-Donald and Jo Anne Petersen Endowed Research Fund
Period: 11/1/2010-4/30/2012
Principal Investigator: David G. Beer, Ph.D.
Co-Investigators: Guoan Chen
$50,000 total costs.
Clinical Molecular Imaging Center
Principal Investigator: Tom Wang (David G. Beer, Co-Investigator, 12% effort)
Agency: National Cancer Institute
U54 CA136429-01, Period: 10/01/08 – 8/30/11
$72,398 direct costs
Molecular Signatures of Lung Cancer
Principal Investigator: David Carbone, (David G. Beer, Ph.D., 15% effort)
Agency: National Cancer Institute
Type: 1U01 CA114771-06: Period: 6/1/2010 to 5/31/2011
David G. Beer, Ph.D.
2/9/16
3
$31,353 total costs
Molecular Studies of Esophageal Adenocarcinoma-Competitive Renewal
Principal Investigator: David G. Beer, Ph.D., (40% effort)
Agency: National Cancer Institute
Type: 2 R01 CA071606-09: Period: 06/01/2005 - 05/31/2010
$323,219 total direct costs/yr
Molecular Signatures of Lung Cancer
Principal Investigator: David Carbone, M.D., Ph.D., (David G. Beer, Ph.D., 15% effort)
Agency: National Cancer Institute
Type: 1U01 CA114771-01: Period: 7/01/05- 6/30/10
$57,577 total costs
Validation of Ubiquilin 1 in Lung Cancer
Principal Investigator: David G. Beer, Ph.D., 10% effort
Agency: National Cancer Institute/EDRN
Period: 8/1/08-7/31/09
$40,487 direct costs
Development and Validation of a qRT-PCR Classifier for Lung Cancer Prognosis
Principal Investigator: David G. Beer, Ph.D.
Agency: MICHR/CSTA
Period: 1/01/09 – 12/31/09
$75,000 direct costs only
Development and Validation of a qRT-PCR Classifier for Lung Cancer Prognosis
Principal Investigator: David G. Beer, Ph.D.
Agency: MIIE
Period: 5/15/09 – 3/15/11
$41,674 direct costs only
Humoral Signature of Lung Cancer
Principal Investigator: David G. Beer, Ph.D., 10% effort
Agency: National Cancer Institute/EDRN
Period: 9/01/05-8/31/07
$100,000 total direct costs
Molecular Studies of Esophageal Adenocarcinoma
Principal Investigator: David G. Beer, Ph.D., (40% effort)
Agency: National Cancer Institute
Type: CA 71606-01A1: Period: 7/01/00- 6/30/05
$1,125,000 total direct costs
Gene Expression Profiling of Squamous Cell Carcinomas of the Lung
David G. Beer, PI, 10% effort
David G. Beer, Ph.D.
2/9/16
4
Agency:Veridex Co.
Period: 5/01/04-1-30-05
Amount: $120,000 total costs.
Great Lakes-New England Clinical Epidemiology Center
Principal Investigator: D. Brenner, M.D.
D. Beer, Co-Investigator, 15% effort
Agency: National Cancer Institute
Type: U01 CA 86400: Period: 4/01/00-3/30/05
Amount: $1,112,132 total costs
Subproject: $49,520 direct costs
Lung Validation Study
Principal Investigator: David G. Beer, Ph.D., 10% effort
Agency: National Cancer Institute
Order No. 263-MQ-319735
Period: 9/25/03-9/25/04, $99,282 total costs
The goals are to investigate gene expression in human lung adenocarcinomas utilizing
gene profiling technologies.
Toward a Molecular Classification of Tumors
David G. Beer, Principal Investigator -Lung Project (20% effort)
Project Principal Investigator: Samir Hanash, M.D., Ph.D.
Agency: National Cancer Institute
Type: U19 CA 85953: Period: 10/1/99-9/30/04
$82,600/yr direct costs
Biomarker Development Laboratory
Principal Investigator: S. M. Hanash, M.D., Ph.D., (David G. Beer, 5% effort)
Agency: National Cancer Institute
Type: U01 CA 84982: Period: 10/1/99-9/30/04
$530,000 total annual direct costs
University of Michigan Surgical Oncology Training Program
David G. Beer, PI (Temporary)
T32 CA009672-14 Period: 09/13/04-06/30/03
$272,833 total annual direct costs
The Study of Human Mutation
Principal Investigator: David G. Beer, Ph.D., 10% effort replacing Dr. James
(deceased) as Principal Investigator in last year of the grant.
Agency: National Cancer Institute
CA 26803: Period 9-1-83- to 12/31/01
Amount: $1,116,724 total year 17.
Neel
Molecular Studies of Esophageal Adenocarcinoma
David G. Beer, Ph.D.
2/9/16
5
Principal Investigator: David G. Beer, Ph.D., 40% effort
Agency: National Cancer Institute
Type: CA 71606-01A1: Period: 6/01/97- 5/30/00,
$697,390 total direct costs
Evaluation of Selective Cox-2 inhibitors in Barrett’s Esophagus
Principal Investigator: David G. Beer, Ph.D.
Agency: Pharmacia
Period 7-1-00-6-30-01
$76,515 total costs
National Institutes of Health/NCI, 12/01/96-11/30-98
Phase II Clinical Trial of Difluoromethylornithine (DFMO) in Barrett's Esophagus,
15% effort.
NO1-CN-55107-32 (D. Brenner, PI)
Amount: $1,800,000 total costs.
Risk Factors in Barrett's Metaplasia
American Cancer Society, 1996-1999, PI.
$300,000 total costs.
Altered Gene Expression During Mouse Lung Carcinogenesis.
National Institutes of Health, 1990-1996, RO1-CA-46433, PI.
$246,281.
Role of AP-1 in K-ras Mediated Lung Cell Transformation
American Cancer Society, 1993-1995, RO1-CN35D, PI.
$150,000.
Role of AP-1 in K-ras Mediated Lung Cell Transformation.
American Cancer Society, 1993, RO1-CN35C,
PI. $34,000.
Renewal: Regulation of Mouse Lung Tumor Susceptibility and
American Cancer Society, 1991-1992, RO1-CN35B, PI.
$106,636.
Development
Regulation of Mouse Lung Tumor Susceptibility and Development.
American Cancer Society, 1989-1990, RO1-CN35A, PI.
$107,126.
Glucocorticoid Regulation of Normal and Neoplastic Lung
Pharmaceutical Manufacturers Association Foundation, 1988-1989, PI.
$20,000.
Development,
Genetics of Pulmonary Tumor Susceptibility
David G. Beer, Ph.D.
2/9/16
6
Speas Foundation, 1988, PI.
$20,000.
Altered Gene Expression in Urethan-induced Lung Tumors
Biomedical Research Support Grant (NIH), 1987, PI.
Kansas University of Medical Center, $15,000.
National Institutes of Health, 1984-1986, CA-07652.
McArdle Laboratory, University of Wisconsin.
Individual NRSA Postdoctoral Fellowship, Experimental Pathology.
HONORS AND AWARDS
1981-1983
1982
1983
1983
1984
2001
2002
Elected University of Colorado, School of Pharmacy Graduate
Student Representative and Graduate Committee Member.
Rho Chi Honor Society.
University of Colorado, Graduate School Foundation Fund
Award.
American Society for Pharmacology and Experimental
Therapeutic Graduate Student Travel Award.
University of Colorado, Harold Heim Research Award.
UM Workplace 2001 Award: Exemplary Achievement
UM Medical School TAMS Award
MEMBERSHIPS IN PROFESSIONAL SOCIETIES
The Society for Developmental Biology, 1988 - 2001.
American Association for Cancer Research (AACR), 1988 - present.
American Association for the Advancement of Science (AAAS), 1984 - present.
Society for Experimental Biology and Medicine, 1993- 2001.
International Association for the Study of Lung Cancer (IASLC)-2005-present
EDITORIAL POSITIONS, BOARDS AND PEER-REVIEW SERVICE
Study Sections:
1987-1991
1986
1987
1991-1992
1993-2001
1998, 1999
1999
2000
David G. Beer, Ph.D.
Study Section Member, American Cancer Society, Kansas
Chapter.
Ad Hoc Grant Reviewer, National Science Foundation.
American Cancer Society Priority Grant Reviewer.
Ad Hoc Study Section Member, Carcinogenesis and Nutrition,
American Cancer Society.
Department of Surgery Research Advisory Committee.
Grant Reviewer for Ohio Cancer Research Associates.
Merit Grant Reviewer for Department of Veteran Affairs.
Grant Reviewer for Northwest Cancer Research Fund,
2/9/16
7
2000, 2001
2000, 2001
2001
2001-2004
2002-2007
2002
2002
2003
2003
2003
2003
2004
2004
2004
2004
2005
2005
2005
2005
2006
2006
2006
2006
2006
2006
2007
2007
2007
2007
2008
2008
2008
2008
2009
2009
2009
2009
2009
2009
2010
2011
David G. Beer, Ph.D.
Liverpool, UK.
Grant Reviewer for Molecular Genetics 2 Study Section for U.S.
Army Breast Cancer Program, DOD.
Merit Grant Reviewer for Department of Veteran Affairs
Grant Reviewer, Dutch Cancer Society.
Biomedical Research Council (BMRC), University of Michigan
ACS Study Section Member, Carcinogenesis (CNE)
Member, NCI site visit team.
NCI Esophageal Study Group Member
Member, NCI site visit team.
Scientific Advisory Board Member, Windber Research Institute,
Windber, PA.
Study Section member, California-TRDRP
Grant Reviewer, Cancer Research UK
Grant Reviewer Danish Cancer Society
Grant Reviewer Italian Association for Cancer Research (AIRC)
Study Section Member, California-TRDRP
Grant Reviewer, Nova Scotia Health Research Foundation
Study Section member, California-TRDRP
Grant Reviewer, NCI Special Emphasis Panel
Grant Reviewer, The Prince Charles Hospital Foundation, Australia
Grant Reviewer, NCI Molecular Oncogenesis study section
Study Section Co-Chair, Carcinogenesis, Nutrition and the Environment,
American Cancer Society.
Grant Reviewer, Cancer Research UK
Grant Reviewer, Swiss Cancer League
Site Visit Member, NCI, Laboratory for Comparative Carcinogenesis
Grant Reviewer, Kentucky Lung Cancer Research Program
Member, UMCCC Cancer Research Committee
Chair, Carcinogenesis, Nutrition and the Environment, American Cancer
Society.
Grant Reviewer, The Cancer Research Society, Health Canada
Grant Reviewer, Cancer Research UK
Grant Reviewer, California TRDRP
Grant Reviewer ACS, Carcinogenesis (CNE)
Grant Reviewer Cancer UK
Grant Reviewer, Kentucky Lung Cancer Research Program
Grant Reviewer, FAMRI Lung Cancer Program
Grant Reviewer, California TRDRP
Site Visit Member, NCI-EDRN, UT-Southwestern Medical Center
Grant Reviewer, Kentucky Lung Cancer Research Program
Grant Reviewer, Cancer UK
Grant Reviewer, Dutch Cancer Society
Grant Reviewer, NCI-Challenge Grants
Grant Reviewer, California TRDRP
Grant Reviewer, California TRDRP
2/9/16
8
2011
Queensland
2011
section
2011
201120102012
2012
20112012
Board
20122013
Board
Editorial Boards:
Grant Reviewer, The Prince Charles Hospital Foundation,
Grant Reviewer, NCI ad hoc member Cancer Genetics study
WCLC2011 Scientific Committee
Department of Surgery, Promotions Research Track Committee
Admissions Committee PIBS/Cancer Biology graduate program
Grant Reviewer, Kentucky Lung Cancer Research Program
Grant Reviewer and Chair, California TRDRP
GI SPORE Senior Scientific Advisory Board
University of Minnesota Cancer Center, Scientific Advisory
Director, UMCCC Cancer Biology Summer Internship program
University of Minnesota Cancer Center, Scientific Advisory
2001-Associate Editor, Clinical Cancer Research
2003-2004 Associate Editor, 2005- Editorial Board, Transactions of
the Integrated Biomedical Informatics and Enabling Technologies
Symposium (TIBETS)
2003- Associate Editor, International Journal of Oncology
2005- Associate Editor, Cancer Research
2006-Editorial Board,
Featured Cover for February International Journal of Oncology
2007-Editorial Board, Translational Oncology
2010- Associate Editor, Carcinogenesis
2010- Associate Editor, Journal of Thoracic Oncology
2011-Editorial Board, Translational Research
Ad Hoc Reviewer for the Following Journals 2004-2011:
New England Journal of Medicine
PLOS
Nature Medicine
Nature Reviews Cancer
Molecular Medicine
Journal of the National Cancer Institute
Gastroenterology
Journal of Clinical Oncology
International Journal of Cancer
Proceedings of the National Academy of Science
Neoplasia
European Journal of Cancer
Molecular and Cellular Proteomics
Additional Training:
1984, NCI-Sponsored Workshop on "Histopathobiology of Neoplasia", Aspen, CO.
1986, Workshop on "In Situ Hybridization", Tufts University,
David G. Beer, Ph.D.
2/9/16
9
Boston, MA.
1988, NCI Sponsored two-week workshop on: "Somatic Cell and Molecular Genetics",
Eleanor Roosevelt Cancer Institute, Denver, CO.
TEACHING ACTIVITIES
University of Michigan:
Research Teaching:
1991
Jerome Seid, M.D., Hematology-Oncology Resident.
1991-1992
Mazin Al-Kasspooles, Medical Student.
1992-1994
Philip Bongiorno, M.D., General Surgery Resident.
1992
Richard Whyte, M.D.,Thoracic Surgery Resident.
1992-1993
Eric Lesser, Undergraduate Biology Student.
1993-1994
Lee Huo, Undergraduate Summer Fellowship Student.
1993-1994
William Rachwal, M.D., General Surgery Resident.
1993-1994
Mark Iannettoni, M.D., Thoracic Surgery Resident.
1993
David Webster, Medical Student.
1995
Bruce Leuchter. premedical Student.
1995
Stan Lee, Medical Student.
1996
Ted Skolaris, Kevin Schafer, undergraduate students.
1996-1998
Steve Hughes, M.D., General Surgery Resident.
1996-1997
Oliver Soldes, M.D., General Surgery Resident.
1996
Carrie Sutton, Justin Moy, undergraduate students.
1997
Keith Compton, Iran Thompson, Medical Students
1997-1998
David Corteville, Marcy Coash, UROP students
1998-2000
Sanjeev Aggarwal, M.D., General Surgery Resident.
1998Lin Lin, M.D., Ph.D, Post-doctoral Fellow.
1998-1999
Neeju Ravikant, M.D., Ph.D, Post-doctoral Fellow.
1999
Puja Singh, Hari Kumar, undergraduate students.
2000-2001
Hideo Umezu, M.D., Visiting Research Scholar, Japan
2000
Theodore Lin, Medical student summer grant project
2000-2001
Hari Kumar, Honors thesis student research advisor
2001-2002
Chris Moran, M.D. General Surgery Resident
2001
Michael Prescott, Medical student summer grant project
2002
Andrew Heaford, Medical student summer grant project
2001
Susie Lee, Student of Public Health, summer project.
Andrew Heaford, Medical Student summer project.
2002-2004
Jules Lin, General Surgery Resident,
2002- 2006
Duna Raoof, undergraduate student.
HasemTabbaa, undergraduate student.
2004-2005
Anika Kumar, engineering student
2007-2009
Daniel Albertus, undergraduate Honors student.
2007-2009
Chris Seder, Wibi Hartojo, General Surgery Residents
2007-2009
Tasneem Kausar, graduate student.
2010Jiwon Lee, graduate student.
2010Igor Rybkin, M.D, PhD, Medical Oncology Resident
2010Ernest Nadal Alforja, M.D., Medical Oncology Resident
David G. Beer, Ph.D.
2/9/16
10
201120122012201220122013-
Alyssa Cates, graduate student rotation
Carla Ramos, graduate student rotation
Daysha Ferrer Torres, Graduate student rotation
Katie Speilbauer, Cancer Research Summer Intern
Ali Bazzi, Medical Student SBRP summer program
Nancy Pinnell, graduate student rotation
Ph.D Exam/Dissertation Committee:
2003 Spencer Huang, Biostatistics
2006 Chad Creighton, Bioinformatics Preliminary Exam Committee, Ph.D.
Thesis Committee
2008 Sinjan Wang, Biostatistics
2008 Dhruv Sud, Bioengineering
2009-2012 John R. Prensner, M.D., Ph.D. Dissertation committee, MSTP
program
2010-2012 Gwyneth Halstead-Nussloch, Cancer Biology
2011- Heather Waline, Preliminary exam committee, Dissertation committee
2011- Mentor T32 Oncology Training grant
2011- Mentor T32 Surgical Oncology Training grant
2011- Advisory Committee T32 Biostatistics Training grant
2012- Brittany Bowman, Dissertation committee, Cancer Biology
2013- Anirban Sahu, Dissertation committee
2013- Brendan Veeneman, Dissertation committee
2013- Allison Fullenkamp, Dissertation committee, Cancer Biology
2013- Melanie Krook, Dissertation committee, Cancer Biology
2013- Linbo Zhao, Dissertation committee, Cancer Biology
Presentations:
1991-present. Radiation Oncology/Cancer Biology Seminars.
1991-present. Thoracic Surgery Laboratory Seminars.
May 1992, Moses Gunn Surgery Research Conference,“ EGFR/ErbB2 Gene
Alterations in Human Esophageal Adenocarcinomas”.
Sept. 25, 1992, 3rd Annual Cancer Research Conference, American Cancer
Society, “Analysis of EGFR and ErbB2 Genes in Human Esophageal
Adenocarcinomas and Barrett’s Esophagus”.
November, 1992. Department of Surgery Seminar, "New Insights into
Human Esophageal Cancer".
February, 1993. Cancer Center, Carcinogenesis Program Seminar.
May, 1993, Moses Gunn Surgery Research Conference, "Intestinal
Differentiation and p53 Gene Alterations in Barrett's Esophagus and
Adenocarcinoma".
May 1994, Moses Gunn Surgery Research Conference, laboratory presented
two posters and one oral presentation.
Nov. 18, 1994, 4th Annual Cancer Research Conference, American Cancer
David G. Beer, Ph.D.
2/9/16
11
Society, laboratory presented two posters.
January 27, 1995. Department of Surgery Seminar, "Short-term organ culture
of Barrett's mucosa-A new model to study epithelial regulation".
May 1995, Moses Gunn Surgery Research Conference, laboratory presented
one oral presentation.
October 28, 1994. University of Michigan Cancer Center, Chemoprevention
Group, "Barrett's Metaplasia".
November 16, 1995, Department of Internal Medicine, Seminar.
Nov. 17, 1995, Annual Cancer Research Conference, American Cancer
Society, Michigan State University, presented poster.
January 17, 1996, Department of Pharmacology, Seminar.
May 1996, Moses Gunn Surgery Research Conference, oral presentation.
October 3, 1996, Department of Surgery Grand Rounds.
October 23, 1996, Department of Anatomy and Cell Biology, Seminar.
May 1997, Moses Gunn Surgery Research Conference, laboratory presented
one oral presentation and one poster.
May 1998, Moses Gunn Surgery Research Conference, laboratory presented
one oral presentation and two posters.
May 1999, Moses Gunn Surgery Research Conference, laboratory presented
one oral presentation and one poster.
April 2000, Moses Gunn Surgery Research Conference, laboratory presented
two oral presentations.
May 2001, Moses Gunn Surgery Research Conference, laboratory presented
one oral presentation and two posters.
September 4, 2001, Thoracic Oncology Research Conference Seminar
May 2002, Moses Gunn Surgery Research Conference, laboratory presented
one oral presentation and two posters.
November 4, 2002, Thoracic Oncology Research Conference Seminar
May 2003, Moses Gunn Surgery Research Conference, laboratory presented
one oral presentation and four posters. Lin Lin received outstanding poster award.
May 2004, Moses Gunn Surgery Research Conference, laboratory presented two oral
presentation and three posters. Jules Lin received “Young Investigator” award and
Charles Miller outstanding poster award.
May 2005, Moses Gunn Surgery Research Conference
May 2006, Moses Gunn Surgery Research Conference
Lectures:
December 11, 1993, Department of Surgery, "Tumor Biology" given to General
Surgery Residents.
December 3, 1994, Department of Surgery, "Tumor Biology" given to General
Surgery residents.
December 10, 1994. Thoracic Surgery Didactic Series, " Molecular Biology of
Thoracic Neoplasms".
December 1995, Department of Surgery, "Tumor Biology" given to General
Surgery residents.
February 1, 15, 22 and March 21, 1996: Lectures on Molecular Biological
David G. Beer, Ph.D.
2/9/16
12
Techniques given to General Surgery Residents.
September 17, 1996: Micro/Immuno/Path 553. Carcinogenesis.
September 21, 1997: Micro/Immuno/Path 553. Carcinogenesis.
September 15, 1998: Micro/Immuno/Path 553. Carcinogenesis.
September 16, 1999: Micro/Immuno/Path 553. Carcinogenesis.
September 14, 2000:Micro/Immuno/Path 553. Carcinogenesis.
September 14, 2000:Organogenesis Graduate Program. “Organogenesis and
Carcinogenesis of the Esophagus”
November 18, 2000: Molecular genetics of lung and esophageal cancer,
Thoracic Surgery Didactic Conference.
September 18, 2001:Micro/Immuno/Path 553. Carcinogenesis.
December 6, 2001: Micro/Immuno/Path 553. Molecular Profiling.
February 12, 2002: K30 Translational Research Course: Application of Gene and Protein
Profiling to the Medical Sciences
September 12, 2002:Micro/Immuno/Path 553. Chemical Carcinogenesis.
December 5, 2002: Micro/Immuno/Path 553. Molecular Profiling.
February 7, 2003: Biostatistics: Gene Expression Techniques
February 21, 2003: Biostatistics: Gene Expression Techniques
September 8, 2003:Micro/Immuno/Path 553. Chemical Carcinogenesis.
September 14, 2004:Micro/Immuno/Path 553. Chemical Carcinogenesis.
November 13, 2004: Molecular genetics of esophageal cancer,
Thoracic Surgery Didactic Conference.
September 13, 2005:Micro/Immuno/Path 553. Chemical Carcinogenesis.
September 12, 2006:Micro/Immuno/Path 553. Chemical Carcinogenesis.
January 29, 2007: Thoracic Oncology Update, Cancer Center Grand Rounds
February 7, 2007, Esophageal Cancer Genetics lecture, Thoracic Surgery
February 14, 2007, Hematology Oncology Fellows lecture
September 10, 2007:Micro/Immuno/Path 553. Chemical Carcinogenesis.
September 11, 2008:Micro/Immuno/Path 553. Chemical Carcinogenesis.
December 10, 2008:Hematology Oncology Fellows lecture.
September 22, 2009:Micro/Immuno/Path 553. Chemical Carcinogenesis.
January 26, 2010, PIBS 507, Translational Research
September 21, 2010:Micro/Immuno/Path 553. Chemical Carcinogenesis.
September 13, 2011:Micro/Immuno/Path 553. Chemical Carcinogenesis.
October 13, 2011, Society of Biology Students: Lung Cancer.
September 11, 2012:Micro/Immuno/Path 553. Chemical Carcinogenesis.
University of Kansas Medical Center:
Courses and Academic Lectures:
1987 Drug Metabolism and Disposition, Graduate
Students, 8 students, 1 - two hour lecture.
Toxicology, Graduate Students, 8 students, 2 - one
hour lectures.
1988 Nursing Pharmacology (Blood and Endocrine Unit)
100 nursing students, 7-one hour lectures.
1989 Medical Pharmacology (Consultant to 19 students)
David G. Beer, Ph.D.
2/9/16
13
1990
1991
to 8
170 students, 1 semester, medical students.
Drug Metabolism and Disposition, Graduate
students, 10 students, 1-two hour lecture.
Toxicology, Graduate Students, 10 students, 2-two
hour lectures.
Medical Pharmacology, (Consultant to 21 students)
160 students and gave 2-one hour lectures, medical
students.
Advanced Toxicology, graduate students,
10 students,gave 1- two hour lecture.
Cellular and Molecular Pharmacology, 13
Graduate students, gave 2-two hour lectures.
Medical Pharmacology, 165 medical students, gave 1one hour lecture.
Toxicology, University of Missouri, Department of
Pharmacology and Toxicology, 3-one hour lectures
graduate students.
Guidance of Graduate Students and Postdoctoral Fellows (Kansas):
Directed the Ph.D. thesis of two graduate students:
Edwin O. Nuzum: graduated with Ph.D., August 15, 1990.
Laurie A. Hanson: graduated with Ph.D., April 16, 1992.
Supervised the following postdoctoral fellow:
Kurt A. Droms, Ph.D. 1990 - 1991.
Supervised the research training of the following graduate students during research rotations (4-6
months) in my laboratory:
Aida Howell
1987
Laurie Pan
1988
Monty Eberhart
1988
Angela Hahn
1989
Robin Pearse
1989
Clarissa Haugness
1990
Jennifer Wagner
1991
Universities of Colorado and Wisconsin:
Courses and Academic Lectures:
1980-1981
Co-instructor of Pathology Course, School of Pharmacy
Students,University of Colorado, 80 students, 1
semester course. I gave eight one hour lectures
COMMITTEE AND ADMINISTRATIVE SERVICES
University of Michigan:
1992
David G. Beer, Ph.D.
Cancer Center Committee for Animal Care Facility.
2/9/16
14
1993
Planning
1991-present
1993-2001
2000
2001-2004
Department of Surgery, Molecular Biology Program
Committee.
Director, Thoracic Surgery Tumor Biology Laboratory.
Department of Surgery, Research Advisory Committee.
Lung Cancer Advisory Committee, State of Michigan.
Biomedical Research Advisory Council (BMRC).
University of Kansas Medical Center:
Member of Speas Foundation Cancer Review Board, 1987.
Member, American Cancer Society Small Grant Review Board, 1987, 1989-90.
Co-organizer of Department Journal Club, 1988 - 1991.
Member Radiation Safety Committee, 1989 - 1991.
Member University of Kansas Travel Committee, 1989 - 1991.
Member Department of Pharmacology Graduate Committee, 1988-1990.
Member Flossie West Cancer Grant Review Board, 1990.
Dissertation: Biochemical and Histochemical Studies on the Regulation of
Normal and Neoplastic Lung Development, 1984.
CONSULTING POSITIONS
2004
2005
2008
2008
2010
External Scientific Advisor, Vanderbilt University Lung Spore
External Advisory Committee, NYU Cancer Center
Advisory committee for CR-UK strategic workshop on esophageal
cancer, March 2008
External Scientific Advisor, Washington University Lung Spore
External Advisory Committee, University of Minnesota Cancer Center
EXTRAMURAL INVITED PRESENTATIONS
University of Michigan
October 14, 1992, "Molecular Biology of Esophageal Cancer-Implications for
New Prognostic Factors", American College of Surgeons Annual Clinical
Congress, New Orleans, LA.
March, 1993, "Methods for Allelic-Specific Gene Expression", Society for
Toxicology Annual Meeting, New Orleans, LA.
April, 1993, Thoracic Surgery Biology Club, "Intestinal Differentiation in
Barrett's Esophagus", Meeting of the American Association for Thoracic
Surgery, Chicago, IL.
June 24, 1994, Lyman A. Brewer Lecture, Esophageal Cancer: From Molecular
Biology to Esophagectomy", The Western Thoracic Surgical Association,
Squaw Creek, CA.
October 21, 1994. The Ohio State University, Department of Preventative
Medicine, "Role of Intestinal Differentiation in Esophageal Cancer".
April 28, 1996. American Assoc. Thoracic Surgery, San Diego CA. Invited
Lecture.
November 22, 1996. American Cancer Society Seventh Annual Meeting,
David G. Beer, Ph.D.
2/9/16
15
Invited Speaker.
January 15, 1998, Wayne State University. Genetic Alterations in Esophageal
Cancer. Invited Lecture.
May 22, 1998, Department of Surgery Research Seminar, "New Experimental
Approaches to Study Barrett's Adenocarcinoma".
September 27, 1998. Boston Barrett’s Symposium. “Chemoprevention of
Barrett’s Metaplasia”
March 26, 1999, University of Michigan Cancer Center Grand Rounds.
“Esophageal Cancer”.
May 4, 1999, Division of Nephrology, University of Michigan. “Gene
Amplification Events in Barrett's Adenocarcinoma".
June 23, 1999, Axys Pharmaceuticals, San Diego CA, “Barrett’s Metaplasia and
the Identification of Genes Associated with Esophageal Adenocarcinoma
Development”.
August, 1999, Monsanto, St. Louis, MO.“Identification of Genes Associated
with Esophageal Adenocarcinoma Development”.
December 1999. Organogenesis Center Symposium“Origins of Barrett’s
metaplasia”
March 9, 2000, Eppley Cancer Institute, University of Nebraska. “Identification
of novel gene amplification events in esophageal adenocarcinoma.”
Sept 3, 2000 6th OESO Conference on Barrett Esophagus, Paris, France: What is
the in vivo value of chromosomal 9p21 allelic loss and CDKN2 gene
mutation in detecting neoplastic progression before aneuploidy and
cancer?
October 27, 2000, “Esophageal Cancer Genetics”, American College of
Surgeons meeting, Chicago, IL.
February 16, 2001, Department of Biochemistry and Molecular Biology,
Medical College of Ohio, Toledo,"Barrett's Metaplasia: Risk Factors and
Genetic Alterations Associated with Adenocarcinoma Development".
February 23, 2001, “Gene expression profiles define a high-risk group among patients
with stage I lung adenocarcinomas”, Department of Surgery, University of Michigan.
March 9, 2001, General Thoracic Surgical Club, Captiva Island Florida, two lectures “The
human genome project: Implications for Thoracic surgery”, Use of molecular profiling for
assessing patient prognosis in thoracic neoplasms”.
March 24, 2001, “Gene expression profiles define a high-risk group among patients with
stage I lung adenocarcinomas”, Tumor vaccine and cell therapy working group
meeting, New Orleans, LA.
April 19, 2001, “Microarray analysis of lung cancer”, Wayne State, Institute of Chemical
Toxicology, MI.
September 6, 2001, “Molecular Analysis of Lung Cancer using Genomics and
Proteomics”, Central Society for Clinical Research, Chicago Il.
October 16, 2001, Proteomic Analysis of Lung Adenocarcinomas, EDRN Seattle WA.
November 8, 2001, “Molecular Profiling of Lung Cancer” Director’s Challenge Meeting,
Bethesda MD.
November 14, 2001, “Gene and Proteomic Profiling for Predicting Patient Survival in
Early Stage Lung Cancer”, Cellular and Molecular Biology Department, University
David G. Beer, Ph.D.
2/9/16
16
of Michigan.
January 7, 2002, “Gene Expression Analysis of Lung Cancer”, Lung Spore Meeting,
Denver CO.
January 14, 2002, “Gene and Protein Profiling of Lung Adenocarcinoma”, Department of
Pathology, University of Michigan.
February 19, 2002, Seminar presentation at Pharmacia Co., St. Louis MO.
March 12, 2002, Gordon Conference on New Frontiers in Cancer Detection and
Diagnosis.
April 2, 2002, University of Kansas Cancer Center, two invited talks, Cancer Center and
Department of Pharmacology, Toxicology and Therapeutics.
April 6, 2002, AACR, San Franscisco, CA.
April 18, 2002, NCI-Frederick MD.
April 30, 2002 Affymetrix Working Group Meeting, Chicago Il.
May 6, 2002, NCI, Directors Challenge Presentation, Washington, DC.
June 5, 2002, Quebec City, Quebec.
June 6, 2002, Montreal, Quebec.
June 27, 2002, NCI/EORTC presentation, Washington DC.
November 19, 2002, Dept. of Pathology, University of Pittsburgh.
January 30, 2003, School of Pharmacy, University of Colorado, Denver, CO.
March 2, 2003, Tumor Markers:Discovery to Practice, Santa Barbara, CA.
March 29, 2003, Current Trends in Lung Cancer, Houston, TX.
April 19, 2003, Johnson and Johnson Co., La Jolla CA.
May 13, 2003, Cambridge Healthtech Institute’s Macroresults for Microarrays, Boston,
MA.
May 17, 2003, American Thoracic Society, Lung Proteomics Post-Graduate Course,
Seattle WA.
June 27, 2003, Lung Cancer Conference, Maui, HI.
Oct 31, 2003, Keynote Speaker 3rd International Early Lung Cancer Detection Workshop,
Liverpool UK.
November 13, 2003, CAMDA Keynote Speaker, Duke University, NC.
November 17, 2003, Speaker ACOS, Seoul Korea.
December 4, 2003, Ohio State University.
February 20, 2004, Targeted Therapies for the Treatment of Lung Cancer Meeting,
Highlight Topic Speaker, San Diego CA.
May 14, 2004, Messina Conference on Cancer Pharmacogenomics, Sicili, Italy.
June 21, 2004, Barrett’s Chemoprevention Symposium, New York, NY.
July 3, 2004, 5th International Lung Cancer Congress, Kauai, HI.
October 8, 2004, University of Michigan Bioinformatics Program
November 4, 2004, Directors Challenge Meeting Bethesda, MD
November 6, 2004, Consensus Conference on BAC, New York NY
November 12, 2004, Department of Surgery Research Seminar, University of Michigan
February 11, 2005, Proteomic analyses in lung cancer, Targeted Therapies for the
treatment of lung cancer, Steamboat Springs, CO.
February 26, 2005, Molecular staging of lung cancer, AACR Special Conference, San
Diego CA.
July 4, 2005, Expression profiling of lung cancer, IASLC meeting, Barcelona, Spain.
David G. Beer, Ph.D.
2/9/16
17
Oct 27, 2005, Keynote Speaker, 4th International Early Lung Cancer Detection
Workshop, Liverpool UK.
November 11, 2005, Lung Cancer: A translational focus, Washington DC
December 2, 2005, Washington University School of Medicine, St. Louis MO
December 9, 2005, Symposium on management of early lung cancer, Vancouver BC
January 25, 2006, Lung Spore Meeting, LA California
February 2, 2006, EDRN Meeting Washington DC
February 7, 2006, University of Minnesota Cancer Center, Minneapolis MN
March 1, 2006, Department of Surgery Grand Rounds, West Virginia University, School
of Medicine, Morganstown WV.
March 1, 2006, Cell and Molecular Biology Seminar Series, West Virginia University
Cancer Center, Morganstown WV.
October 14, 2006, 11th World Congress on Advances in Oncology, Crete, Greece
November 30, 2006, Ontario Cancer Institute, Toronto, Canada
March 13, 2007, JCA-AACR Special Joint Conference, Nagoya, Japan
April 14, 2007, AACR Annual Meeting, Los Angeles, CA.
September 4, 2007, 12th World Conference on Lung Cancer, Seoul, Korea
September 15, 2007, 7th Annual Lung Cancer Symposium, University of Cincinnati
October 14, 2007, 3rd Haifa Cancer Prevention Workshop, Haifa, Isreal
December 6th, 2007, Karmanos Cancer Institute, Detroit MI
April 23-26 2008, ESMO-IASLC meeting, Geneva, Switzerland
July 10, 2008, 1st International Lung Conference, Liverpool, UK
October 22, 2008, Department of Surgery, UM
December 4, 2008, SPECs meeting, Vanderbilt TN
March 6, 2009, SSO Pheonix AZ
May 29, 2009, National Lung Cancer Partnership Meeting, Orlando FL
August 4, 2009, 13th World Conference on Lung Cancer, San Francisco CA
November 1, 2009, 19th Hiroshima Lung Cancer Conference, Hiroshima, Japan
November 17, 2009: Division of Gastroenterology, University of Michigan, Ann Arbor
December 3, 2009, Editors, Nature Journals Advisory Committee, New York, NY
February 6, 2010: Lung Cancer Study Group, Barcelona, Spain
February 9, 2010, Nature Meeting on Systems Biology and HIV, Atlanta, GA.
February 19, 2010, Critical Issues in Lung Cancer, Stockholm, SE
February 25, 2010, Targeted Therapies in Lung Cancer, Santa Monica, CA.
March 8, 2010: University of Michigan Hematology/Oncology Seminar Series
April 7, 2010: Translational Research in Medicine Seminar Series, UMCCC
May 17, 2010: ATS Meeting, New Orleans LA
October 6, 2010, University of Michigan Epigenetic Cancer Seminar Series
October 28, 2010, NFGC Meeting, Clearwater FL
November 15, 2010, Celgene Advisory Meeting, Zurich, Switzerland
March 9, 2011, Cell and Developmental Biology, University of Michigan
March 10, 2011, Hematology and Oncology, Columbia University, NY
April 10, 2011, IASLC/ASCO/ECMO Targeted Therapy of Lung Cancer, Malta
October 20, 2011, Oncology Network for Excellence: MET, Falls Church VA
November 3, 2011, Esophageal Support Group, University of Michigan
January 9, 2012, AACR-IASLC, Molecular Origins of Lung Cancer, Plenary Lecture
David G. Beer, Ph.D.
2/9/16
18
March 10, 2012, Moffitt Cancer Center, Tampa FL
May 7, 2012, Memorial Sloan Kettering, NY, Grand Rounds and Thoracic Oncology
Lecturer
May 11th 2012, BETRnet NCI, Bethesda MD
September 2, 2012, OSEO Como Italy
October 10 2012, University of Colorado, Denver
March 7, 2013, CONPO, Barcelona, Spain
July 8, 2013, BETRnet NCI, Bethesda MD
University of Kansas Medical Center
April 9, 1987, Kansas Cancer Research Conference, University of Kansas
Medical Center, KS., "Proto-oncogene Expression in Preneoplastic and
Neoplastic Liver Lesions".
November 30, 1988, Symposium on "Mouse Liver Carcinogenesis", Austin,
TX., "Proto-oncogene and Gap-Junction Protein Expression in Rodent
Liver Neoplasms".
September 28, 1989, Seminar at School of Basic Life Sciences, University of
Missouri, Kansas City, MO., "Activation and Expression of the K-ras
Oncogene in Murine Lung Tumors and Lung Tumor Cell Lines".
March 23, 1990, Symposium on "Mouse Lung Carcinogenesis" National
Institutes of Environmental Health Sciences, Research Triangle Park,
NC., "Expression of the Glucocorticoid Receptor and K-ras Genes in
Urethan-induced Mouse Lung Tumors and Transformed Cell
Lines".
May 9, 1990, Department of Pharmacology and Toxicology, Michigan State
University, East Lansing, MI., "Role of K-ras Activation and Expression in
Mouse Lung Carcinogenesis".
February 11, 1991, Invited to give a 3-hour series of lectures on "Oncogenes
and Oncogenesis" in the Department of Pharmacology and Toxicology,
University of Missouri at Kansas City, MO.
Universities of Colorado and Wisconsin
May 13, 1986, Department of Anatomy and Cell Biology, State University of
New York, Syracuse, NY.
May 8, 1986, Department of Anatomy, University of California at San
Francisco, CA.
June 20, 1986, Presentation at Symposium on "Mechanisms of Cellular
Toxicity and Adaption", Northwestern University, Chicago,
PATENTS
Hanash S, Misek D, Hinderer R, Beer D and Brichory F: Annexins and Autoantibodies used as
Markers for Lung Cancer or Oesophageal Cancer. European Patent EP1200832A1, Awarded
May 2, 2002.
Hanash S, Misek D, Hinderer R, Beer DG and Brichory F.: Annexin Proteins and
Autoantibodies as Serum Markers for Cancer. US Patent 6,645,465, Awarded Nov 11, 2003.
David G. Beer, Ph.D.
2/9/16
19
Hanash S, Misek D, Hinderer R, Beer D and Brichory F: Annexin Autoantibodies used as
Markers for Lung Cancer. European Patent EP1734368A2, Awarded December 20, 2006.
Hanash S, Misek D, Hinderer R, Beer D and Brichory F: Annexins as Markers for Lung or
Esophageal Cancer. European Patent EP2051079A3, Awarded June 10, 2009.
Hanash S, Misek D, Hinderer R, Beer D and Brichory F: Annexin Proteins and Autoantibodies
as Serum Markers for Cancer. U.S. Patent 7,955,602, Awarded June 7, 2011.
Hanash S, Misek D, Hinderer R, Beer D and Brichory F: Annexin Proteins and Autoantibodies
as Serum Markers for Cancer. U.S. Patent 7,759,081, Awarded July 27, 2010.
Beer DG, Kardia S, Giordano TJ, Taylor J, Hanash SM, Huang CC, Misek DE, Thomas D. and
Kuick R: Expression Profile of Lung Cancer. Patent Application Filed.
Beer DG, Taylor J, G.Chen and Sinae Kim: Lung Cancer Signature. Patent Application Filed
May 16, 2012.
BIBLIOGRAPHY
Peer-Reviewed Publications
1.
Hjelle JJ, Grubbs JH, Beer DG, Petersen DR: Inhibition of rat liver aldehyde
dehydrogenase by carbon tetrachloride. J Pharmacol Exp Ther 219: 821-826, 1981.
PMID: 7299699
2.
Beer DG, Hjelle JJ, Petersen DR, Malkinson AM: Ca2+-activated proteolytic activity in
rat liver mitochondria. Biochem Biophys Res Comm 104:1276-1283, 1982. PMID:
6762879
3.
Hjelle JJ, Grubbs JH, Beer DG, Petersen DR: Time course of the carbon tetrachlorideinduced decrease in mitochondrial aldehyde dehydrogenase activity. Toxicol Appl
Pharmacol 67: 159-165, 1983. PMID: 6836571
4.
Beer DG, Cunha GR, Malkinson AM: Autoradiographic demonstration of the specific
binding and nuclear localization of 3H-dexamethasone in adult mouse lung. Lab Invest
49: 725-734, 1983. PMID: 6656202
5.
Beer DG, Butley MS, Malkinson AM: Developmental changes in the endogenous ca2+stimulated proteolysis of mouse lung cAMP-dependent protein kinases. Arch Biochem
Biophys 228: 207-219, 1984. PMID: 6320733
6.
Butley MS, Beer DG, Malkinson AM: Functional changes in the regulatory subunit of the
type II cyclic adenosine 3':5'-monophosphate-dependent protein kinase isozyme during
normal and neoplastic lung development. Cancer Research 44: 2689-2697, 1984. PMID:
6327022
7.
Beer DG, Malkinson AM: Localization of specific [3H]dexamethasone binding in
urethan-induced mouse lung tumors. Cancer Research 44: 3546-3553, 1984. PMID:
6744279
8.
Beer DG, Butley MS, Cunha GR, Malkinson AM: Autoradiographic localization of
specific [3H]dexamethasone binding in fetal lung. Dev Biol 105: 351-364, 1984. PMID:
6479444
9.
Butley MS, Stoner GD, Beer DG, Beer DS, Mason RJ, Malkinson, AM: Changes in
cyclic AMP-dependent protein kinases during the progression of urethan-induced mouse
lung tumors. Cancer Research 45:3677-3685, 1985. PMID: 2990675
10.
Beer DG, Malkinson AM: A genetic influence on type 2 or clara cell origin of pulmonary
adenomas in urethan-treated mice. J Natl Cancer Inst 75: 963-969, 1985. PMID:
David G. Beer, Ph.D.
2/9/16
20
3863993
11.
Beer DG, Schwarz M, Sawada N, Pitot HC: Expression of H-ras and c-myc
protooncogenes in isolated gamma-glutamyl transpeptidase positive rat hepatocytes and in
hepatocellular carcinomas induced by diethylnitrosamine. Cancer Research 46: 2435-2441,
1985. PMID: 2870798
12.
Thaete LG, Beer DG, Malkinson AM: Genetic variation in the proliferation of murine
pulmonary type II cells: basal rates and alterations following urethan treatment. Cancer
Research 46: 5335-5338, 1986. PMID: 3756882
13.
Schwarz M, Peres G, Beer DG, Maor M, Buchmann A, Kunz W, Pitot HC: Expression of
albumin messenger RNA detected by in situ hybridization in preneoplastic and neoplastic lesions
in rat liver. Cancer Research 46: 5903-5912, 1986. PMID: 2428487
14.
Beer DG, Pitot HC: Biological markers characterizing the development of preneoplastic
and neoplastic lesions in rodent liver. Arch Toxicol 10: 68-80, 1986. PMID: 2883960
15.
Glauert HP, Beer DG, Reddy JK, Schwarz M, Xu Y, Goldsworthy TL, Coloma J, Pitot
HC: Induction of altered hepatic foci by the administration of hypolipidemic peroxisome
proliferators alone or following a single dose of dimethylnitrosamine. Cancer Research
46: 4601-4606, 1986.
16.
Beer DG, Zweifel KA, Simpson DP, Pitot HC: Specific gene expression during
compensatory renal hypertrophy in the rat. J Cell Physiology. 131: 29-35, 1987. PMID:
2883191
17.
Beer DG, Neveu MJ, Paul D, Rapp UR, Pitot HC: Expression of the c-raf proto-oncogene
and a gap junction protein in preneoplastic foci and rat liver neoplasms. Cancer Research
48: 1610-1617, 1988. PMID: 2894242
18.
Pitot HC, Beer DG, Hendrich S: Gene expression during multistage
hepatocarcinogenesis. Scand J Gastroenterol (Suppl. 151), 52-61, 1988. PMID: 3227317
19.
Beer DG, Pitot HC: Proto-oncogene activation during chemically-induced
hepatocarcinogenesis in rodents. Mutation Res 220:1-10, 1989.
20.
Beer DG, Neveu MJ: Proto-oncogene and gap junction protein expression in
rodent
liver neoplasms. Prog Clin Biol Res 331:293-309, 1990.
21.
Pan YH, Nuzum EO, Beer DG: K-ras activation and expression in transformed mouse
lung cell lines. Mol Carcinogenesis 3: 279-286, 1990.
22.
Nuzum EO, Malkinson AM, Beer DG: Specific K-ras activating mutations may
determine the development of mouse lung adenomas or adenocarcinomas. Mol
Carcinogenesis 3: 287-295, 1990.
23.
Hanson LA, Nuzum EO, Jones BC, Malkinson AM, Beer, DG: Expression of the
glucocorticoid receptor and K-ras genes in urethan-induced mouse lung tumors and
transformed cell lines. Exp Lung Res 17: 371-387, 1991.
24.
Stahl BU, Beer DG, Weber LWD, Lebofsky M, Rozman K: Decreased hepatic
phosphoenolpyruvate carboxykinase gene expression after 2,3,7,8-tetrachlorodibenzo-pdioxin treatment: implications for the acute toxicity of chlorinated dibenzo-p-dioxins in
the rat. Arch Toxicol Suppl. 15, pp. 151-155, 1991.
25.
Stahl BU, Beer DG, Weber LWD, Rozman K: Reduction of hepatic phosphoenolpyruvate
carboxykinase (PEPCK) activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is due
to decreased mRNA levels. Toxicology 79:81-95, 1993.
26.
Droms KA, Hanson LA, Malkinson AM, Beer DG: Altered dexamethasone
responsiveness and loss of growth control in mouse lung tumor cells. Int J Cancer
David G. Beer, Ph.D.
2/9/16
21
53:1017-1022, 1993.
27.
Al-Kasspooles M, Moore JH, Orringer MB, Beer DG: Amplification and
overexpression of the EGFR and erbB2 genes in human esophageal
adenocarcinomas. Int J Cancer 54:213-219, 1993.
28.
Wu, GD, Beer DG, Moore JA, Orringer MB, Appelman HD, Traber PG: Sucraseisomaltase gene expression in Barrett’s esophagus and adenocarcinoma.
Gastroenterology 105:837-844, 1993.
29.
Li J, Beer DG: K-ras mRNA regulation in nontransformed mouse lung cells.
Mol
Carcinogenesis 8:193-201, 1993.
30.
Mahacek ML, Beer DG, Frank TS, Ethier SP: Finite proliferative lifespan in vitro of a
human breast cancer cell strain isolated from a metastatic lymph node. Breast Cancer
Research and Treatment, 28:267-276, 1993.
31.
Bongiorno PF, Whyte RI, Lesser EJ, Moore JH, Orringer MB, Beer DG: Alterations of
K-ras, p53 and erbB2/neu in human lung adenocarcinomas. J Thoracic Cardiovascular
Surgery 107:590-595, 1994.
32.
Moore JH, Lesser EJ, Erdody DH, Natale RB, Orringer MB, Beer DG: Intestinal
differentiation and p53 gene alterations in Barrett’s esophagus and esophageal
adenocarcinomas. Int J Cancer 56:487-493, 1994.
33.
Wei R-Q, Chen G-H, Beer DG, Kunkel SL, Bolling SF. Inhibition of tumor necrosis
factor production by lymphocytes from anti-TNF-treated, cardiac-allographed rats. J
Surgical Res 56:601-605, 1994.
34.
Bongiorno PF, Al-Kasspooles, Lee SW, Rachwal WJ, Moore JH, Whyte RI,
Orringer MB and Beer DG. E-cadherin expression in primary and metastatic
neoplasms and in Barrett's esophagus. Br J Cancer 71:166-172, 1995.
35.
Rachwal WJ, Bongiorno PF, Ethier SP, Whyte RI, Orringer MB, Beer DG. Expression
and activation of erbB2 and EGFR in lung adenocarcinomas. Br J Cancer 72:56-64,
1995.
36.
Li J and Beer DG. Effect of increased glucocorticoid responsiveness in transformed
mouse lung cells. Mol Carcinogenesis 13:135-145, 1995.
37.
Li J, Johnson TA, Hanson LA and Beer DG: Loss of Glucocorticoid-dependent growth
inhibition in transformed mouse lung cells. Mol Carcinogenesis 16:213-220, 1996.
38.
Johnson TA, Li J, and Beer DG: Influence of glucocorticoid receptor on c-fos
inducibilty in activated ras-containing mouse lung cells. Mol Carcinogenesis
17:7077, 1996.
39.
Iannettoni MD, Lee SS, Bonnell MR, Sell TL, Whyte RI, Orringer MB, and Beer DG.
The detection of Barrett's adenocarcinoma of the gastric cardia with sucrase isomaltase
and p53. Ann Thorac Surg 62:1460-1466, 1996.
40.
Tsai TT, Bongiorno PF, Orringer MB, Beer DG. Detection of P53 nuclear protein
accumulation in esophageal brushings and biopsies. Cancer Detection and Prevention
21(4):326-331, 1997.
41.
Michael D, Beer DG, Wilke CW, Miller DE, Glover TW. Frequent deletions
of
FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinoma.
Oncogene
15:1653-1659, 1997.
42.
Hughes SJ, Nambu Y, Rehmtulla A, Hamstra D, Orringer MB, Beer DG. Lack
of cell
surface Fas/APO-1 expression in esophageal adenocarcinomas. Cancer
Res 55:5571-5578,
1997.
David G. Beer, Ph.D.
2/9/16
22
43.
Nambu Y, Hughes SJ, Rehmtulla A, Hamstra D, Orringer MB, Beer DG. Lack of cell
surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest. 10:1-9,
1998.
44.
Regalado SP, Nambu Y, Iannettoni MD, Orringer MB, Beer DG. Abundant expression of
the protein villin in Barrett's esophagus and esophageal adenocarcinomas. Mol
Carcinogenesis 22:182-189, 1998.
45.
Glover TW, Hoge A, Miller DE, Ascara-Wilke JE, Dagenais SL, Wilke CM, Dierick, and
D.G. Beer. The murine FHIT gene is highly similar to its human orthologue and maps to
a common fragile site region. Cancer Res. 58:3409-3414, 1998.
46.
Petty EM, Kalikin LM, Orringer MB, Beer DG. Distal chromosome 17q loss in Barrett's
adenocarcinomas and gastric cardia adenocarcinomas: Implications for tumorigenesis.
Mol Carcinogenesis 22:222-228, 1998.
47.
Nambu Y, Iannettoni MD, Orringer MB, Beer DG. Unique expression patterns and
alterations in the intestinal protein Villin in primary and metastatic pulmonary
adenocarcinomas. Mol Carcinogenesis 23:234-242, 1998.
48.
Hughes SJ, Glover TW, Zhu XX, Kuick R. Thoraval D, Orringer MB, *Beer DG,
*Hanash S. (*shared senior authorship). A novel amplicon at 8p22-23 results in
overexpression of cathepsin B in esophageal adenocarcinoma. Proc Natl Acad Sci (USA)
95:12410-12415, 1998.
49.
Soldes OS, Kuick RD, Thomson IA, Hughes SJ, Orringer MB, Iannettoni MD, Hanash
SM, Beer DG. HSP27 is highly abundant in normal esophagus and markedly diminished
in Barrett's metaplasia and esophageal adenocarcinomas. Br. J. Cancer 79:595-603, 1999.
50.
MacLennan AJ, Orringer MB, Beer DG. Identification of intestinal-type Barrett's
metaplasia by using the intestinal-specific protein villin and esophageal brush cytology.
Mol Carcinogenesis 24:137-143, 1999.
51.
Hughes SJ, Morse MA, Weghorst CM, Kim H, Watkins PB, Guengerich FP,
Orringer MB, Beer DG. Cytochromes P450 is expressed in proliferating cells
in
Barrett's metaplasia. Neoplasia 1: 145-153, 1999.
52.
Compton KR, Orringer MB, Beer DG. Induction of glutathione S-transferasepi in
Barrett's metaplasia and Barrett's adenocarcinoma cell lines. Mol Carcinogenesis. 24:128-136,
1999.
53.
Chiang P-W, Beer DG, Wei W-L, Orringer MB, Kurnit DM. Detection of erbB2
amplifications in tumors and sera from esophageal carcinoma patients. Clin Cancer
Res.5:1381-1386, 1999.
54.
Lin L, Aggarwal S, Glover TW, Orringer, MB, Hanash S, Beer DG. A minimal critical
region of the 8p22-23 amplicon in esophageal adenocarcinomas defined using STSamplification mapping and quantitative PCR includes the GATA-4 gene. Cancer Res.
60:1341-1347, 2000.
55.
Aggarwal S, Taneja N, Lin L, Iannettoni MD, Orringer MB, Rehemtulla A, Beer DG.
Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of
Bax and translocation of cytochrome C independent of Cox-2 expression. Neoplasia 2 (4) 1-11,
2000.
56.
Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of
cyclooxygenase-2 induces apoptosis in human esophageal adenocarcinoma cells. Cancer
Res 60:5767-5772, 2000.
57.
Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, Yin J,
David G. Beer, Ph.D.
2/9/16
23
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
Fleisher AS, Abraham JM, Beer DG, Sidransky D, Huss HT, Demeester TR, Eads CA,
Laird PW, Ilson DH, Kelsen DP, Harpole D, Moore M, Danenberg KD, Danenberg PV,
Meltzer SJ. Hypermethylated APC DNA in plasma and prognosis in patients with
esophageal adenocarcinoma. JNCI 92(22): 1805-1811, 2000.
Lin L, Prescott MS, Zhu Z, Singh P, Chun SY, Kuick RD, Hanash S, Orringer, MB,
Glover TW, Beer DG. Identification and characterization of a 19q12 amplicon in
esophageal adenocarcinomas reveals cyclin E as the best candidate gene for this
amplicon. Cancer Res. 60:7021-7027, 2000.
Fang, JM, Arlt MF, Burgess AC, Dagenais SL, Beer DG, Glover TW. Translocation
breakpoints in FHIT and FRA3B in both homologs of chromosome 3 in an esophageal
adenocarcinoma. Genes, Chromosomes & Cancer 30:292-298, 2001.
Brichory FM, Misek DE, Yim A-M, Krause MC, Giordano TJ, Beer DG, Hanash SM. An
immune response manifested by the common occurrence of annexins I and II
autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci
(USA) 98 (17) 9824-9829, 2001.
Brichory FM, Beer DG, Le Naour F, Giordano TJ, Hanash S. Proteomics-based
identification of protein gene product 9.5 as a tumor antigen that induces a humoral
immune response in lung cancer. Cancer Res. 61:7908-7912, 2001.
Oh JMC, Brichory F, Puravs E, Kuick R, Wood C, Rouillard JM, Tra J, Kardia S, Beer
D, Hanash S. A database of protein expression in lung cancer. Proteomics 1:1303-1319,
2001.
Giordano TJ, Shedden KA, Schwartz DR, Kuick R, Taylor JMG, Lee N, Misek DE,
Greenson JK, Kardia SLR, Beer DG, Rennert G, Cho KR, Gruber SB, Fearon ER, S
Hanash. Organ-specific molecular classification of lung, colon and ovarian
adenocarcinomas using gene expression profiles. Am. J. Pathol. 159:1231-1238, 2001.
Hanash S, Brichory F, Beer DG. A proteomic approach to the identification of lung
cancer markers Dis. Markers 17(4):295-300, 2001.
Arlt MF, Miller DE, Beer DG, Glover TW. Molecular characterization of FRAXB and
comparative common fragile site instability in cancer cells. Genes, Chromosomes &
Cancer 33: 82-92, 2002.
Chen, G, Gharib TG, Huang CC, Taylor JMG, Kardia SLR, Misek DE, Giordano, TJ,
Iannettonni MD, Orringer MB, Hanash S, Beer DG. Discordant protein and mRNA
expression in lung adenocarcinomas. Cellular and Molecular Proteomics 1:304-313.
2002.
Chen, G, Gharib TG, Huang CC, Thomas DG, Sheddon KA, Taylor JMG, Kardia SLR,
Misek DE, Giordano, TJ, Iannettonni MD, Orringer MB, Hanash S, Beer DG. Proteomic
analysis of proteins overexpressed in lung adenocarcinomas with correlation to mRNA
abundance. Clin Cancer Res 8:2298-2305, 2002.
Gharib TG, Chen G, Wang H, Huang CC, Prescott MS, Sheddon KA, Misek DE, Thomas
DG, Giordano, TJ, Taylor JMG, Yee, J, Orringer MB, Hanash S, Beer DG. Proteomic
analysis of cytokeratin isoforms associated with survival in lung adenocarcinoma.
Neoplasia 4(5) 440-448, 2002.
Beer DG, Kardia SLR, Huang CC, Misek DE, Lin L, Chen, G, Gharib TG, Giordano, TJ,
Thomas DG, Lizyness ML, Kuick R, Taylor JMG, Iannettonni MD, Orringer MB,
Hanash S. Gene expression profiles predict survival of patients with lung
adenocarcinoma. Nature Medicine 8:816-824, 2002.
David G. Beer, Ph.D.
2/9/16
24
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
Lin L, Miller CT, Contreras JI, Prescott MS, Yee J, Orringer MB, Misek DE, Hanash
SM, Glover TW, Beer DG. The Hepatocyte Nuclear Factor 3 Alpha FOXA1 (HNF3)
gene on chromosome band 14q13 is amplified and overexpressed in esophageal and lung
adenocarcinomas. Cancer Res 62:5273-5279, 2002.
Misek DE, Chang CL, Kuick R, Hinderer R, Giordano TJ, Beer DG, Hanash SM.
Oncogenic mutation of the microtubule regulator Op18. Cancer Cell 2(3):217-226, 2002.
Moran CJ, Arenberg DA, Huang CC, Giordano, TJ, Misek DE, Iannettonni MD, Orringer
MB, Hanash S, Beer DG. Rantes expression by lung adenocarcinomas is a predictor of
survival in stage I patients. Clin Cancer Res 8:3803-3812, 2002.
Creighton C, Hanash S, Beer DG. Gene expression patterns define pathways correlated
with loss of differentiation in lung adenocarcinomas. FEBS Letters 540:167-170, 2003.
Chen G, Gharib TG, Thomas DG, Huang CC, Misek DE, Giordano TJ, Iannettoni MD,
Orringer MB, Hanash S, Beer DG. Proteomic Analysis of elf-5A in lung
adenocarcinomas. Proteomics 3:496-504, 2003.
Chen, G, Gharib TG, Huang CC, Taylor JMG, Kardia SLR, Misek DE, Giordano, TJ,
Iannettonni MD, Orringer MB, Hanash S, Beer DG. Oncoprotein 18 is highly expressed
in poorly differentiated lung adenocarcinomas and correlates with increased transcription.
Mol Cell Proteomics 2(2):107-116, 2003.
Wu R, Lin L, Beer DG, Ellenson LH, Lamb BJ, Rouillard J-M, Kuick R, Hanash S, Cho
KR. Amplification and overexpression of L-myc oncogene in ovarian carcinomas. Am. J.
Pathol. 165(5):1603-1610, 2003.
Joe AK, Liu H, Xiao D, Soh J-W, Pinto JT, Beer DG, Piazza GA, Thompson WJ,
Weinstein IB. Exisulid and CP248 induce growth inhibition and apoptosis in human
esophageal adenocarcinoma and squamous carcinoma cells. J Exp Ther Oncol. 3(2):8394, 2003.
Chen X, Ning L, Wang S, Wu N, Hong J, Jiao X, Krasna MJ, Beer DG, Yang CS.
Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory
effects of bestatin. JNCI 95(14):1053-1061, 2003.
Miller CT, Aggarwal S, Lin TK, Contreras JI, Dagenais SL, Orringer MB, Glover TW,
Beer DG, Lin L. Amplification and overexpression of the dual-specificity Yak-related
kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas indicate a potential
oncogenic role in tumorigenesis. Cancer Res. 63: 4136-4143, 2003.
Miller CT, Chen G, Gharib TG, Thomas DG, Misek DE, Giordano TJ, Yee J, Orringer
MB, Hanash S, Beer DG. Increased c-crk proto-oncogene expression is associated with
an aggressive phenotype in lung adenocarcinomas. Oncogene 22(39):6006-6013, 2003.
Miller CT, Lin L, Moy JR, Schipper M, Normolle D, Brenner DE, Iannettoni MD,
Orringer MB, Beer DG. Gene amplification in esophageal adenocarcinomas and Barrett’s
with high-grade dysplasia. Clin. Cancer Res. 9:4819-4825, 2003.
Sheddon KA, Taylor JMG, Giordano TJ, Kuick R, Misek DE, Rennert G, Schwartz DR,
Gruber S, Logsdon C, Simeone D, Greenson JK, Cho KR, Beer DG, Fearon ER, Hanash
S. Accurate Molecular classification of human cancers based on gene expression using a
simple classifier with a pathologic tree-based framework. Am. J. Pathol. 163(5):19851995, 2003.
Chen G, Gharib TG, Wang H, Huang CC, Thomas DG, Sheddon KA, Misek DE, Taylor
JMG, Giordano, TJ, Iannettoni MD, Orringer MB, Hanash S, Beer DG. Protein
expression profiles predict patient survival in stage I lung adenocarcinoma. Proc. Natl.
David G. Beer, Ph.D.
2/9/16
25
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
Acad. Sci (USA) 100:13537-13542, 2003.
Beer DG. Gene Expression Profiles Predict Survival in Lung Adenocarcinoma. Am. J.
Oncol.Rev. 2(5):258-263, 2003.
Chen G, Wang H, Miller CT, Thomas DG, Gharib TG, Misek DE, Giordano TJ, Orringer
MB, Hanash S, Beer DG. Reduced selenium-binding protein 1 expression is associated
with poor outcome in lung adenocarcinomas. J. Pathol. 204:321-329, 2004.
Lahn M, Chen Su, Shuyu Li, Marcio Chedid, Kimberly R. Hanna, Jeremy R. Graff,
George E. Sandusky, Doreen Ma, Clet Niyikiza, Karen L. Sundell, William J. John,
Thomas J. Giordano, David G. Beer, Blake M. Paterson, Eric Wen Su, Thomas F. Bumol,
Expression Levels of Protein Kinase C-α in Non–Small-Cell Lung Cancer, Clinical Lung
Cancer, Volume 6, Issue 3, November 2004, Pages 184-189, ISSN 1525-7304,
10.3816/CLC.2004.n.032.
Cuezva JM, Chen G, Alonso A, Isidoro A, Misek DE, Hanash SM, Beer DG. The
bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer
diagnosis and prognosis. Carcinogenesis 25;1157-1163, 2004.
Lin J, Raoof D, Thomas DG, Greenson GK, Giordano TJ, Robinson GS, Barve RA,
Orringer MB, Beer DG. L-type amino acid transporter-1 overexpression mediates uptake
of melphalan in Barrett’s adenocarcinoma. Neoplasia 6:74-84, 2004.
Gharib TG, Chen G, Huang CC, Misek DE, Iannettoni MD, Orringer MB, Hanash S,
Beer DG. Genomic and proteomic analyses of VEGF and IGFBP3 in lung
adenocarcinomas. Clin. Lung Cancer 5(5): 307-312, 2004.
Shammas MA, Koley H, Beer DG, Li C, Goyal RK, Munshi NC. Growth arrest,
apoptosis and telomere shortening of Barrett’s associated adenocarcinoma cells by a
telomerase inhibitor. Gastroenterology 126:1337-1346, 2004.
Moore TC, Jepeal LI, Boylan MO, Singh SK, Boyd N, Beer DG, Chang AJ,Wolfe MM.
Gastrin stimulates receptor-mediated proliferation of human esophageal adenocarcinoma
cells. Regul. Pept. 120:195-203, 2004.
Daly EB, Chen G, Sun L, Friedlander M, Goldstein D, Beer DG, Chesterman CN, Hogg
PJ. Blood level of phosphoglycerate kinase does not correlate with presence or extent of
tumour. Int. J. Biol. Markers 19(2):170-2, 2004.
Lin J and Beer DG. Molecular Biology of Upper GI Malignancies. Seminars in
Oncology. 31:476-486, 2004.
Lin J, Lin L, Thomas DG, Giordano TJ, Robinson GS, Barve RA, Orringer MB, Beer
DG. Melanoma-associated Antigens in Esophageal Adenocarcinoma: Identification of
Novel MAGE-A10 Splice Variants. Clin. Cancer Res. 10:5708-5716, 2004.
Chen X, Wang S, Wu N, Sood S, Wang P, Jin Z, Beer DG, Giordano TJ, Lin Y, Shih WJ,
Lubet RA, Yang CS. Overexpression of 5-lipoxygenase in rat and human esophageal
adenocarcinoma and inhibitory effects of Zileuton and Celecoxib on carcinogenesis. Clin.
Cancer Res. 10:6703-6709, 2004.
Chang AC, Beer DG. Lung cancer genomic profiling. Lung cancer: principles and
practice 4(4):1-12, 2004.
Lahn M, Su C, Li S, Chedid M, Hanna K, Graff JR, Sandusky GE, Ma D, Niyikaza C,
Sundell KL, John WJ, Giordano TJ, Beer DG, Paterson BM, Su W, Bumol TF.
Expression levels of protein kinase C-alpha in non-small cell lung cancer. Clinical Lung
Cancer 6(3) 184-189, 2004.
Mahidhara RS, Queiroz De Oliveira, Kohout J, Beer DG, Lin J, Watkins SC, Robbins
David G. Beer, Ph.D.
2/9/16
26
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
PD, Hughes SJ. Altered trafficing of fas and subsequent resistance to fas-mediated
apoptosis occurs by a wild-type p53-independent mechanism in esophageal
adenocarcinoma. J Surg Res 123(2):302-311, 2005.
Dobbin K, Beer DG, Meyerson M, Yeatman T, Gerald W, Jacobson J, Conley B, Lugo T,
Buetow K, Heiskanen M, Simon R, Minna J, Girard L, Misek D, Kuick R, Taylor J,
Hanash S, Golub TR, Naoki K, Hayes DN, Ladd-Acosta C, Enkemann S, Viale A,
Giordano T. Inter-laboratory comparability study of cancer gene expression analysis
using oligonucleotide microarrays. Clin Cancer Res 11:565-572, 2005.
Steiner FA, Hong JA, Guo Z-S, Beer DG, Fischette MR, Chen GA, Kassis ES, Nguyen
DM, Lee S, Trepel JB, Schrump DS. Sequential decitabine/depsipeptide FK228 treatment
induces tissue factor pathway inhibitor (TFPI-2) expression in cancer cells. Oncogene.
2005 Feb 07; [Epub ahead of print]
Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y, Olaru A, Wang S, Mori Y, Deacu
E, Kan T,. Krasna MJ, Beer DG, Abraham JM, Feng Z, Schmiegel W, Greenwald BD,
Meltzer SJ. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett’s-associated
neoplastic progression and predicts progression risk. Oncogene Apr 11; Epub ahead pf
print, 24(25) 4138-48, 2005.
Chen G, Bhojani MS, Heaford AC, Chang DC, Griffin L, Yu J, Thomas DG, Giordano
TJ, Lin L, Adams D, Orringer MB, Ross BD, *Beer DG, *Rehemtulla A. (*Shared senior
authorship). Phosphorylated FADD induces NF-B, cell proliferation, perturbation in cell
cycle and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad
Sci.USA;102(35):12507-12, 2005.
Miller CT, Lin L, Casper AM, Lim J, Thomas DG, Orringer MB, Chang A, Giordano TJ,
Glover TW, Beer DG. Genomic amplification of MET with boundaries with Fragile site
FRA7G and up-regulation of MET signaling pathways in esophageal adenocarcinomas
Oncogene 2005 Sep 26; [Epub ahead of print]
Bhojani MS, Chen G, Ross BD, Beer DG, Rehemtulla A. Nuclear localized
phosphorylated FADD induces cell proliferation and is associated with aggressive lung
cancer. Cell Cycle 4:11:1476-9, 2005.
W. Zhong, D. Sud, M. Wu, K.A. Merrick, S.D. Merajver, D.G. Beer, and M.-A.Mycek:
Sensing cellular function and molecular activity in vivo using fluorescence lifetime
imaging microscopy (FLIM), in "Novel Optical Instrumentations for Biomedical
Applications II" (C. Depeursinge, Ed.), Proceedings of SPIE-OSA European Conference
on Biomedical Optics (ECBO), Vol. 5864 pp 58-66, 2005.
D. Sud, W. Zhong, D.G. Beer, and M.-A. Mycek: Measurement of intracellular oxygen
levels using fluorescence lifetime imaging microscopy (FLIM), in "Photon Migration and
Diffuse-Light Imaging II" (R. Cubeddu and K. Licha, Eds.), Proceedings of SPIE-OSA
European Conference on Biomedical Optics (ECBO), Vol. 5859 pp 7-16, 2005.
Lin L,Wang Z, Prescott MS, van Dekken H, Thomas DG, Giordano TJ, Chang AC,
Orringer MB, Gruber SB, Moran JV, Glover TW, Beer DG. Dissection of a 2Mb 3q26.3q27 segment reveals multiple forms of genetic instability during the development of
esophageal adenocarcinoma. Genes, Chromosomes and Cancer 2005 Nov 30; [Epub
ahead of print].
Younes M, Georgakis GV, Rahmani M, Beer DG, Albert VR, Younes A. Functional
expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal
adenocarcinoma. Eur J Cancer. 2006 Mar 42(4):542-547. Epub 2006 Jan 19
David G. Beer, Ph.D.
2/9/16
27
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
D. Sud, W. Zhong, D. G. Beer, and M. -A. Mycek. Time-resolved optical imaging
provides a molecular snapshot of altered metabolic function in living human cancer cell
models. Optics Express, 14:4412-4426, 2006.
Fu X, Beer D, Lambeth D, Souza RF, Spechler SJ, Wands J, Behar J, Cao W. cAMP
response element binding protein (CREB) mediates acid-induced NADPH oxidase
NOX5-S expression in Barrett's esophageal adenocarcinoma cells. J. Biol. Chem 2006
May 17; [Epub ahead of print].
Zhao J, Chang AC, Li C, Shedden KA, Thomas DG, Misek DE, Giordano TJ, Beer DG,
Lubman DM. Comparative proteomic analysis of Barrett’s Metaplasia and esophageal
adenocarcinomas using 2-D liquid mass mapping. Mol. Cell. Proteomics, Jul 8 [Epub
ahead of print], 2006.
Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JMG, MacDonald J, Thomas D,
Moskaluk C, Wang Y, Beer DG. Gene Expression Signatures for Predicting Prognosis of
Squamous Cell Lung Carcinomas. Cancer Research. Aug 1;66(15):7466-7472, 2006.
Yoo C, Zhao J, Pal M, Hersberger K, Huber CG, Simone DM, Beer DG, Lubman DM.
Automated integration of Monolith-based protein separation with on-plate digestion for
mass spectrometric analysis of esophageal adenocarcinomas. Electrophoresis [Epub
ahead of print], August 22, 2006.
Huang C-C, Taylor JMG, Beer DG, Kardia SLR. Hidden Markov model for defining
genomic changes in lung cancer using gene expression data. Omics 10(3):276-288, 2006.
McClelland MR, Carskadon S, Zhao L, White ES, Beer DG, Orringer MB, Pickens A,
Chang AC, Arenberg DA. Diversity of the angiogenic phenotype in non-small cell lung
cancer. Am J Respir Cell Mol Biol. 36:343-350, 2006. PMID: 17079777
Wislez M, Beer DG, Wistuba I, Cadranel J, Saijo N, Johnson BE. Molecular Biology,
Genomics, and Proteomics in Bronchioloalveolar Carcinoma: Consensus Conference on
Bronchioloalveolar Cell Carcinoma. J. Thoracic Oncology 1(9) S8-S12, 2006. PMID:
17410000
Lin J, Raoof D, Wang Z, Lin M, Thomas DG, Greenson GK, Giordano TJ, Orringer MB,
Chang AC, Beer DG, Lin L. Expression and effect of inhibition of the ubiquitinconjugating enzyme E2C (UBE2C) in esophageal adenocarcinoma. Neoplasia,
Dec;8(12):1062-1071, 2006. PMID: 17217624
Chen G, Wang X,Yu J, Varambally S, Yu J, Thomas DG, Wang Z, Fielhauer J,Ghosh D,
Giordano TJ, Chang AC, Orringer MB, *Beer DG, *Chinnaiyan AM, (*Shared senior
authorship). Epitomic profiles of humoral immune response associated with diagnosis
and prognosis of lung adenocarcinomas. Cancer Research 2007 Apr 1;67(7):3461-7.
PMID: 17409457
Si J, Fu X, Behar J, Wands J, Beer DG, Souza RF, Spechler SJ, Cao W. NADPH oxidase
NOX5-S mediates acid-induced Cox-2 expression via NF-kB activation in Barrett's
esophageal adenocarcinoma cells. J. Biol. Chem., [Epub ahead of print]. Apr 2, 2007.
PMID: 17403674
Si J, Fu X, Behar J, Wands J, Beer DG, Lambeth D, Chin E, Cao W. STAT5 mediates
Platelet-Activating Factor NADPH oxidase NOX5-S expression in Barrett's esophageal
adenocarcinoma cells. Am J Physiol Gastrointest Liver Physiol. 2007 Oct 18; [Epub
ahead of print]. PMID: 17947454
Jin Z, Mori Y, Yang J, Sato F, Ito T, Cheng Y, Paun B, Hamilton JP, Kan T, Olaru A,
David S, Agarwal R, Abraham JM, Beer D, Montgomery E, Metlzer SJ.
David G. Beer, Ph.D.
2/9/16
28
Hypermethylation of the nel-like 1 gene is a common and early event and is associated
with poor prognosis in early-stage esophageal adenocarcinoma. Oncogene. 2007 Sep
20;26(43):6332-40. Epub 2007 Apr 23. PMID: 17975140
122. Jin Z, Olaru A, Yang J, Sato F, Cheng Y, Kan T, Mori Y, Mantzur C, Paun B, Hamilton
JP, Ito T, Wang S, David S, Agarwal R, Beer DG, Abraham JM, Metlzer SJ.
Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer.
Clin Cancer Res. 2007 Nov 1;13(21):6293-300. PMID: 18199717
123. Weir BA, Getz G, Woo MS, Perner S, Beroukhim R, Ding L, Lin WM, Province MA,
Kraja A, Johnson L, Shah K, Thomas RK, Barletts JA, Borecki IB, Broderick S, Chang
AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar A, Giordano T, Greulich H,
Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna J,
Morgan MB, Nadel M, Orringer MB, Osbourne JR, Ozenberger B, Ramos AH, Robinson
J, Roth JA, Rusch V, Sasaki H, Sato M, Shepard F, Spitz MR, Tsao M-S, Twoney D,
Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q,
Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis W, Pao W, Rubin
MA, Gabriel S, Gibbs R, Varmus H, Wilson RK, Lander E, Meyerson M. Characterizing
the cancer genome in lung adenocarcinoma. Nature 2007 Nov 4(Epub ahead of print).
PMID: 18641660
124. Wang S, Nan B, Zhu J, Beer DG. Doubly penalized Buckley-James method for survival
data with high-dimensional covariates. Biometrics 2007 Aug 3; [Epub ahead of print].
PMID: 17680828
125. Jin Z, Hamilton JP, Yang J, Mori Y, Olaru A, Sato F, Ito T, Kan T, Cheng Y, Paun B,
David S, Beer DG, Agarwal R, Abraham JM, Metlzer SJ. Hypermethylation of the
AKAP12 Promoter is a Biomarker of Barrett's-Associated Esophageal Neoplastic
Progression. Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):111-7. PMID:
18199717
126. DiFeo A, Feld L, Beer DG, Martignetti JA, Narla G. A functional role for KLF6-SV1 in
lung adenocarcinoma prognosis and chemotherapy response. Cancer Res. 2008 Feb 4;
[Epub ahead of print] PMID: 18250346
Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann
A, Weder W, Giordano TJ, Beer DG, Rickman DS, Chinnaiyan AM, Moch H, Rubin MA.
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia. 2008 Mar;10(3):298-302.
PMID: 18320074
127. Shedden K, Taylor JMG, Enkemann SA, Tsao MS, Yeatman TJ, Eschrich S, Jurisica I,
Gerald WL, Venkatraman ES, Meyerson M, Kuick R, Dobbin KK, Lively T, Giordano
TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K,
Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl
M, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Sharma A.
Jacobson JW, Beer DG. Gene Expression-Based Survival Prediction in Lung
Adenocarcinoma: A Multi-Site, Blinded Validation Study Director’s Challenge
Consortium for the Molecular Classification of Lung Adenocarcinoma. Nature Medicine
July 20, 2008(Epub ahead of print). PMID: 18641660
128. Watanabe N, Takaoka M, Sakurama K, Tomono Y, Hatakeyama S, Ohmori O, Motoki T,
Shirakawa Y, Yamatsuji T, Haisa M, Matsuoka J, Beer DG, Nagatsuka H, Tanaka N,
Naomoto Y.Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like
growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro
David G. Beer, Ph.D.
2/9/16
29
129.
130.
131.
132.
133.
134.
135.
136.
137.
and in vivo. Clin Cancer Res. 2008 Jul15;14(14):4631-9. PMID: 18628478
Shammas MA, Qazi A, Batchu RB, Bertheau RC, Wong JY, Rao MY, Prasad M, Chanda
D, Ponnazhagan S, Anderson KC, Steffes CP, Munshi NC, De Vivo I, Beer DG,
Gryaznov S, Weaver DW, Goyal RK.Telomere maintenance in laser capture
microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase
inhibition in vivo. Clin Cancer Res. 2008 Aug 1;14(15):4971-80. PMID: 18676772
Jin Z, Cheng Y, Olaru A, Kan T, Yang J, Paun B, Ito T, Hamilton JP, David S, Agarwal
R, Selaru FM, Sato F, Abraham JM, Beer DG, Mori Y, Shimada Y, Meltzer SJ. Promoter
hypermethylation of CDH13 is a common, early event in human esophageal
adenocarcinogenesis and correlates with clinical risk factors. Int J Cancer. 2008 Nov
15;123(10):2331-6. PMID: 18729198
Albertus DL, Seder CW, Chen G Wang X, Hartojo W, Lin L, Silvers A, Thomas DG,
Giordano TJ, Chang AC, Orringer MB, Bigbee WL, Chinnaiyan AM, Beer DG. AZGP1
expression is epigenetically regulated and its autoantibody predicts survival in lung
adenocarcinoma. J. Thoracic Oncology 2008 Nov;3(11):1236-1244. PMID: 18978557
Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C,
Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC,
Lawrence M, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani
SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf
GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y,
Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H,
Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J,
Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio
RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T,
Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good P, Chang AC, Beer
DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province
MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M,
Wilson RK. Somatic mutations affect key pathways in lung adenocarcinoma. Nature
2008 Oct 23;455(7216):1069-75. PMID: 18948947
Guo NL, Wan YW, Tosun K, Lin H, Msiska Z, Flynn DC, Remick SC, Vallyathan V,
Dowlati A, Shi X, Castranova V, Beer DG, Qian Y. Confirmation of gene expressionbased prediction of survival in non-small cell lung cancer. Clin Cancer Res. 2008 Dec
15;14(24):8213-20. PMID: 19088038
Seder CW, Hartojo W, Lin L, Silvers A, Wang Z, Thomas DG, Giordano TJ, Chen
G,Chang AC, Orringer MB, Beer DG. INHBA Overexpression Promotes Cell
Proliferation and May Be Epigenetically Regulated in Esophageal Adenocarcinoma. J.
Thoracic Oncology. 2009 Feb 23. [Epub ahead of print] PMID: 19240652
Seder CW, Hartojo W, Lin L, Silvers A, Wang Z, Thomas DG, Giordano TJ, Chen G,
Chang AC, Orringer MB, Beer DG. Upregulated INHBA Expression May Promote Cell
Proliferation and Is Associated with Poor Survival in Lung Adenocarcinoma. Neoplasia.
2009 Apr;11(4):388-96. PMID: 19308293
Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, Beer DG. MicroRNA Classifiers
for Predicting Prognosis of Squamous Cell Lung Cancer. Cancer Research. 2009; 69:
(14). July 15, 2009 5776-5783.
Kausar T, Ahsan A, Hasan Md.R, Lin L,Beer DG, Ralhan R. Sperm protein 17 is a novel
marker for predicting cisplatin response in esophageal squamous cancer cell lines. Int J
David G. Beer, Ph.D.
2/9/16
30
138.
139.
140.
141.
142.
143.
144.
145.
Cancer. 2009 Aug 14. [Epub ahead of print] PMID: 19685492
Ramos AH, Dut A, Mermel C, Perner S, Cho J, Lafargue CJ, Johnson LA, Steidl A-C,
Tanaka K, Bass AJ, Barretina J, Weir BA, Beroukhim R, Thomas RK, Minna J, Chirieac
L, Lindeman N, Giordano TG, Beer DG, Wagner P, Wistuba I I, Rubin MA, Meyerson
M. Amplification of Chromosomal Segment 4q12 in Non-small Cell Lung Cancer.
Cancer Biol Ther. 2009 Nov;8(21):2042-50. Epub 2009 Nov 7.PMID: 19755855
Hassan KA, Chen G, Kalemkerian GP, Wicha M, Beer DG. An embryonic stem cell–like
signature identifies poorly-differentiated lung adenocarcinoma but not squamous
carcinoma. Clin Cancer Research 2009 Oct 15;15(20):6386-90. Oct 6. PubMed PMID:
19808871.
Wang XS, Prensner JR, Chen G, Cao Q, Han B, Dhanasekaran SM, Ponnala R, Cao X,
Varambally S, Thomas DG, Giordano TJ, Beer DG, Palanisamy N, Sartor MA, Omenn
GS, Chinnaiyan AM. An integrative approach to reveal driver gene fusions from
paired-end sequencing data in cancer. Nat Biotechnol. 2009 Nov;27(11):1005-11.
Epub 2009 Nov 1. PubMed PMID: 19881495; PubMed Central PMCID: PMC2903743.
Bass A, Watanabe H, Yul S, Mermel C, Perner S, Verhaak R, Kim SY, Wardell L,
Tamayo P Gat-Viks I, Ramos A, Woo MS, Weir B, Gets G, Beroukhim R, O’Kelly M,
Dutt A, Rozenbaltt-Rozen O, Dziunycz P, Komisarof J, Chirieac L, LaFargue V,
Wilbertz T, Ma C, Rao S, Nakagawa H, Stairs DB, Lin L, Giordano TJ, Wagner P, Minna
JD, Gazdar AF, Zhu CQ, Brose MS, Cecconello I, Brose M, Ribeiro U, Marie SK,
Shivdasanil RA, Tsao MS, Rubin M, Wong K, Regev A, Hahn WC, Beer DG, Rustgi A,
Meyerson M. SOX2 is an Amplified Oncogene in Squamous Cell Esophageal and Lung
Carcinomas. Nature Genetics Nov;41(11):1238-42. Epub 2009 Oct 4. PubMed PMID:
19801978.
Beroukhim R, Mermel CH, D Porter, G Wei, S Raychaudhuri, J Donovan, J Barretina1,
JS Boehm, J Dobson, M Urashima, K McHenry, R Pinchback, AH Ligon, J Cho, L
Haery, H Greulich, M Reich, W Winckler, BA Weir, K Tanaka, DY Chiang, AJ Bass, A
Loo, C Hoffman, J Prensner, T Liefeld, D Yecies,nS Signoretti, E Maher, FJ Kaye, H
Sasaki, JE Tepper, JA Fletcher, J Baselga, M Tsao, MA Rubin, PA Janne, MJ Daly, C
Nucera, RL Levine, BL Ebert, S Gabriel, AK Rustgi, CR Antonescu, M Ladanyi, A Leta,
LA Garraway, M Loda, DG Beer, LD True, A Okamoto, SL Pomeroy, S Singer, ES
Lander, G Getz, TR Golub, WR Sellers, M Meyerson. The landscape of copy number
alterations across multiple human cancers. Nature. 2010 Feb 18;463(7283):899905.PMID: 20164920
Boonstra JJ, van Marion R, Beer DG , Lin L, Chaves P, Ribeiro C, Pereira AD, Roque L,
Darnton SJ, Altorki NK, Schrump DS, Klimstra DS, Tang LH, Eshleman JR, Alvarez H ,
ShimadaY, van Dekken H, Tilanus HW, Dinjens WNM. Contaminated Cell Lines
Threaten the Development of Treatment Strategies for Esophageal Adenocarcinoma. J.
Natl. Cancer Inst. 2010 Feb 24;102(4):271-4. Epub 2010 Jan 14.PMID: 20075370
AL Silvers, L Lin, AJ Bass, Z Wang, G Chen, DG Thomas, J Lin, M Meyerson, DG
Beer, AC. Chang. Decreased selenium binding protein 1 (SELENBP1) in esophageal
adneocarcinoma results from post-transcriptional and epigenetic mechanisms and affects
chemosensitivity. Clin Cancer Res. 2010 Apr 1;16(7):2009-21. Epub 2010 Mar 23.PMID:
20332323
Hartojo W, Silvers AL, Thomas DG, Seder CW, Lin L, Rao H, Wang Z, Greenson JK,
Giordano TJ, Orringer MB, Rehemtulla A, Bhojani MS, Beer DG, Chang AC. Curcumin
David G. Beer, Ph.D.
2/9/16
31
146.
147.
148.
149.
150.
151.
152.
153.
154.
promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor
kappaB in esophageal adenocarcinoma. Transl Oncol. 2010 Apr;3(2):99-108. PubMed
PMID: 20360934; PubMed Central PMCID: PMC2847317.
Li M, Anastassiades CP, Joshi B, Komarck CM, Piraka C, Elmunzer BJ, Turgeon
DK, Johnson TD, Appelman H, Beer DG, Wang TD. Affinity Peptide for Targeted
Detection of Dysplasia in Barrett's Esophagus. Gastroenterology. 2010 Nov;139(5):147280. PMID: 20637198.
Bryant CM, Albertus DL, Kim S, Chen G, Brambilla C, Guedj M, Arima C, Travis
WD, Yatabe Y, Takahashi T, Brambilla E, Beer DG. Clinically relevant
characterization of lung adenocarcinoma subtypes based on cellular pathways: an
international validation study. PLoS One. 2010 Jul 22;5(7):e11712. PubMed PMID:
20661423; PubMed Central PMCID: PMC2908611.
King AN, Beer DG, Christensen PJ, Simpson RU, Ramnath N. The vitamin D/CYP24A1
story in cancer. Anticancer Agents Med Chem. 2010 Mar;10(3):213-24. Review.
PubMed PMID: 20184548.
Qazi A, Pai J, Maitah M, Fulciniti M, Pelluru D, Nanjappa P, Batchu RB, Prasad M,
Bryant CS, Rajput S, Gryznov S, Goyal RK, Beer DG, Weaver DW, Munshi NC,
Shammas MA. Anticancer activity of a broccoli derivative, sulforaphane, in Barrett's
adenocarcinoma: Potential use in chemoprevention and as adjuvant in chemotherapy.
Transl Oncol. 2010 Dec 1;3(6):389-99.PMID: 21151478.
G Chen, SH Kim, A King, Lili Zhao, PJ Christensen, Z Wang, DE Brenner, RU Simpson,
and DG Beer, N Ramnath. CYP24A1 mRNA Expression Is Independently Prognostic for
Outcome in Lung Adenocarcinoma. Clin Cancer Res. 2010 Dec 17. [Epub ahead of print]
PMID: 21169243
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG,
Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch
FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M,
Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D,
Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D,
Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V,
Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D. International association for
the study of lung cancer/american thoracic society/european respiratory society
international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol.
2011 Feb;6(2):244-85. PubMed PMID: 21252716.
Meng H, Chen G, Zhang X, Wang Z, Thomas D, Giordano T, Beer DG, Wang MM.
Stromal LRP1 in lung adenocarcinoma predicts clinical outcome. Clin Cancer Res.
Mar21, 2011 Epub ahead of print. PMID: 21325077.
Pal J, Bertheau R, Buon L, Qazi A, Batchu RB, Bandyopadhyay S, Ali-Fehmi R, Beer
DG, Weaver DW, Reis RS, Goyal RK, Huang Q, Munshi NC, Shammas MA. Genomic
evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51,
homologous recombination and Alu sequences in the genome. Oncogene. 2011 Mar 21.
[Epub ahead of print] PubMed PMID: 21423218.
Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA,
Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS,
Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H,
Koker M, Leenders F, Gabler F, Querings S, Ansén S, Brambilla E, Brambilla C,
David G. Beer, Ph.D.
2/9/16
32
155.
156.
157.
158.
159.
160.
161.
162.
163.
164.
165.
166.
Lorimier P, Brustugun OT, Helland A, Petersen I, Clement JH, Groen H, Timens W,
Sietsma H, Stoelben E, Wolf J, Beer DG, Tsao MS, Hanna M, Hatton C, Eck MJ, Janne
PA, Johnson BE, Winckler W, Greulich H, Bass AJ, Cho J, Rauh D, Gray NS, Wong
KK,
Haura EB, Thomas RK, Meyerson M. Mutations in the DDR2 kinase gene identify a
novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011 Apr
3;1(1):78-89. PubMed PMID: 22328973; PubMed Central PMCID: PMC3274752.
Ray D, Ahasan A, Helman A, Chen G, Hegde A, Gurjar SR, Zhao L, Kiyokawa H, Beer
DG, Lawrence TS, Nyati MK. Regulation of EGFR protein stability by the HECT-type
ubiquitin ligase SMURF2. Neoplasia 7:570-578, 2011. PMID: 21750651
Suzuki K, SS Kachala, K Kadota, R Shen, DG Beer, VW Rusch, WD Travis, PS
Adusumilli. Prognostic Immune Markers in Non-Small Cell Lung Cancer. Clin Cancer
Res. Aug 15;17(16):5247-56. Epub 2011 Jun 9. 2011. PubMed PMID: 21659461.
Chen G, Kim S, Taylor JMG ,Wang Z, Lee O, Ramnath N, Reddy RM , Lin J, Chang AC,
Orringer MB, Beer DG. Development and validation of a qRT-PCR classifier for lung
cancer prognosis. J. Thoracic Oncology Sep;6(9):1481-7, 2011. PMID: 21792073.
H Gong, S Wang, G Mayer, G Chen, A Stepanova, E Webster, G Leesman, S Singh, DG
Beer. Signatures of Drug Sensitivity in Non-Small Cell Lung Cancer. International
Journal of Proteomics, Vol. 2011. 2011;2011:215496. Epub 2011 Aug 7.PMID:22091388
Lin J, Beer DG. Molecular Predictors of Prognosis in Lung Cancer. Review Article.
Annals of Surgery 2011 Aug 6. [Epub ahead of print].PMID: 21822554.
Chen G, Beer DG. Response to translating cancer complexity to clinical decisions. J
Thorac Oncol. 2011 Sep;6(9):1456-7.
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Powell
CA, Beer DG, Riely GJ, Garg K, Austin JH, Rusch VW, Hirsch FR, Jett J, Gould M.
International Association for the Study of Lung Cancer/American Thoracic
Society/European RespiratorySociety: International Multidisciplinary Classification of
Lung Adenocarcinoma: An Executive Summary. Proc Am Thorac Soc Vol 8. pp 381–
385, 2011.PMID: 21926387
WW Lockwood, KL Thu, L Lin, LA Pikor, R Chari, WL Lam, DG Beer. Integrative
Genomics Identified RFC3 as an Amplified Candidate Oncogene in Esophageal
Adenocarcinoma Clin Cancer Res. 2012 Apr 1;18(7):1936-46. 2012 Feb 10. [Epub ahead
of print]PMID: 22328562
Y-W Wan, DG. Beer, NL Guo Signaling pathway-based identification of extensive
prognostic gene signatures for lung adenocarcinoma. Lung Cancer 2011 Oct 31. [Epub
ahead of print]PMID: 22047960
Lin L, Bass A, Lockwood WW, Wang Z, Silvers AL, DG Thomas, Li W, Chang AC,
Orringer MB, Glover TW, Giordano TJ, Lam W, Meyerson M, Beer DG. Activation of
GATA6 sustains oncogenic survival in esophageal adenocarcinoma. PNAS Feb 28, 2012
[Epub ahead of print] PMID: 22375031
Bandla S, Pennathur A, Luketich JD, Beer DG, Lin L, Bass AJ, Godfrey TE, Litle
VR. Comparative genomics of esophageal adenocarcinoma and squamous cell
carcinoma. Ann Thorac Surg. 2012 Apr;93(4):1101-6. PubMed PMID: 22450065.
Kim SH, G Chen, AN King, CK Jeon, PJ Christensen, L Zhao, RU Simpson, DG
Thomas, TJ Giordano, DE Brenner, B Hollis, DG Beer, N Ramnath.Characterization of
vitamin D receptor (VDR) in lung adenocarcinoma. Lung Cancer May 5 2012 Epub
David G. Beer, Ph.D.
2/9/16
33
ahead of print. PMID: 22564359
167. Dulak AM, S Schumacher, J van Lieshout, Y Imamura, C Fox, B Shim, A Ramos, G
Saksena, S Baca, J Baselga, J Tabernero, J Barretina, P Enzinger, G Corso, F Roviello, L
Lin, S Bandla, J Luketich, A Pennathur, M Meyerson, S Ogino, RA Shivdasani, DG
Beer, TE Godfrey, R Beroukhim, AJ Bass. Genomic analysis of esophageal, gastric, and
colorectal adenocarcinomas demonstrates distinct patterns of genome instability and
oncogenic events. Cancer Res. 2012 Sep 1;72(17):4383-4393. Epub 2012 Jul 2.PMID:
22751462.
Yamauchi M, Yamaguchi R, Nakata A, Kohno T, Nagasaki M, Shimamura T, Imoto S, Saito A,
Ueno K, Hatanaka Y, Yoshida R, Higuchi T, Nomura M, Beer DG, Yokota J, Miyano S, Gotoh
N. Epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage I
lung adenocarcinoma.PLoS One. 2012;7(9):e43923. PMID: 23028479.
168. Cancer Genome Atlas Research Network, Hammerman PS, Hayes DN, Wilkerson
MD,Schultz N, …..Comprehensive genomic characterization of squamous cell lung
cancers. Nature. 2012 Sep 27;489(7417):519-25. doi: 10.1038/nature11404. Epub 2012
Sep 9.PMID:22960745
169. Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, Beer DG, Kalemkerian GP, Wicha
M. Notch pathway activity identifies functional lung cancer stem cells and correlates with
worse survival. Clin Cancer Res. 2013 Feb 26. [Epub ahead of print]PMID:
23444212
Ball D, Mitchell A, Giroux D, Rami-Porta R; IASLC Staging Committee and
Participating Institutions. Effect of tumor size on prognosis in patients treated
with radical radiotherapy or chemoradiotherapy for non-small cell lung cancer. An
analysis of the staging project database of the International Association for the
Study of Lung Cancer. J Thorac Oncol. 2013 Mar;8(3):315-21.PubMed PMID:
23334092.
170. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, Bandla S, Imamura
Y, Schumacher SE, Shefler E, McKenna A, Carter SL, Cibulskis K, Sivachenko A,
Saksena G, Voet D, Ramos AH, Auclair D, Thompson K, Sougnez C, Onofrio RC,
Guiducci C, Beroukhim R, Zhou Z, Lin L, Lin J, Reddy R, Chang A, Landrenau R,
Pennathur A, Ogino S, Luketich JD, Golub TR, Gabriel SB, Lander ES, Beer DG,
Godfrey TE, Getz G, Bass AJ. Exome and whole-genome sequencing of esophageal
adenocarcinoma identifies recurrent driver events and mutational complexity. Nat
Genet. 2013 Mar 24. [Epub ahead of print] PubMed PMID:23525077.
171. Lin J, Beer DG. Update on recent prognostic markers in adenocarcinoma. Lung Cancer
Management (2013) 2(2), 141–152.
172. Sturm MB, BP Joshi, S Lu,C Piraka, BJ Elmunzer RS Kwon, YC Chen, J Zhou, DG
Beer, H Appelman, DK Turgeon, TD Wang. Targeted imaging of esophageal neoplasia
with fluorescent-labeled peptide: first in-humans results. Science Translational Medicine
2013 May 8;5(184):184ra61. doi: 10.1126/scitranslmed.3004733.PMID:23658246.
173. S Rousseaux, A Debernardi, B Jacquiau, A-L Vitte, A Le Bescont, A Vesin, H Mignotte,
D Moro-Sibilot, P-Y Brichon, S Lantuejoul, M Callanan, DG Beer, J-F Timsit, C
Brambilla, E Brambilla, S Khochbin. Germline-like nature of aggressive metastasis-prone
lung cancer cells. Science Translational Medicine 2013 May 22;5(186):186ra66.
174. C Man-Chung Li, G Chen, T Dayton, C Kim-Kiselak, S Hoersch, CA Whittaker, RT
Bronson, DG Beer, MM Winslow, T Jacks. Differential Tks5 isoform expression
David G. Beer, Ph.D.
2/9/16
34
175.
176.
177.
178.
179.
180.
181.
182.
183.
184.
185.
contributes to metastatic invasion of lung adenocarcinoma. Genes and Development 2013
Jul 15;27(14):1557-67.
Sandoval J, J Mendez-Gonzalez, E Nadal, G Chen, FJ Carmona, S Sayols, S Moran, H
Heyn, M Vizoso, A Gomez, M Sanchez-Cespedes, Y Assenov, F Müller, C Bock, M
Taron, J Mora, LA Muscarella, M Pollan, LM Montuenga, E Brambilla, JK Field, L Roz,
GV Scagliotti, R Rosell, DG Beer, M Esteller. A Prognostic DNA Methylation Signature
for Stage I Non-Small Cell lung Cancer. J. Clin. Oncol. (in press)
Shukla S, US Allam, A Ahsan, PM Krishnamurthy, K Marsh, M Rumschlag, G Chen, S
Shankar, C Whitehead, M Schipper, V Basrur, DR Southworth, A, Chinnaiyan, A
Rehemtulla, DG Beer, TS Lawrence, MK Nyati, D Ray. Mutant KRAS protein stability
and GTPase activity is regulated by SMURF2-UBCH5 complex mediated ubiquitination.
(submitted).
Nadal E, G Chen, M Gallegos, L Lin, D Ferrer-Torres, A Truini, Z Wang, J Lin, RM
Reddy, R Llatjos, I Escobar, J Moya, AC Chang, F Cardenal, G Capella, DG Beer.
Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early
stage lung adenocarcinoma. Clin Cancer Res. (resubmitted).
Cancer Genome Atlas Research Network. Diversity of Lung Adenocarcinoma Revealed
by Integrative Molecular Profiling. Nature (submitted).
Grabauskiene S, Bergeron E, Chen G, Chang AC, Lin J, Thomas DG, Giordano TJ, Beer
DG, Morgan MA, Reddy RM. CHK1 Levels Correlate with Sensitization to Pemetrexed
by CHK1 Inhibitors in Non-Small Cell Lung Cancer Cells. (submitted).
Balbin OA, J Prensner, A Sahu, A Yocum, S Shankar, R Malik, D Fermin, M
Dhanasekaran, B Chandler, D Thomas, DG Beer, X Cao, AI Nesvizhski, AM
Chinnaiyan. Reconstructing targetable pathways in lung cancer by integrating
transcriptome, proteome and phosphoproteome. (submitted).
Li H, M Tan, L Jia, D Wei, Y Zhao, G Chen, L Zhao, D Thomas, DG Beer, and Y Sun.
Inactivation of Sag/Rbx2/Roc2 E3 ligase suppresses KrasG12D-driven lung cancer via
blockage of NFB and mTOR. (submitted).
Khan A, Bhojani M, Nyati S, Hamilton C, Coppola J, Chen G, Thomas D, Rao H, Zhang
L, Beer DG, Ross B, Rehemtulla A. Fas-associated Death Domain is a critical mediator
of EGFR-induced induced NF-κB activation. (submitted).
Ramnath N, AN King, W Chen, A Wenzlaff, AG Schwartz, DG Beer and ML Cote.
Genetic Variants of Vitamin D3 Pathway Related-Genes and Non-Small Cell Lung
Cancer (NSCLC) Risk in Women (submitted).
Saintigny P, L Zhang, L Girard, L Xu, LA Byers, HN Kadara, YH Fan, JJ Lee, K
Coombes, DC Lam, PL Chung, MP Wong, WL Gerald, DG Beer, H Shigematsu, M-S
Tsao, FA Shepherd, SM. Lippman, RS Herbst, ES Kim, L Mao, WK Hong, I Wistuba, J
Minna, JV Heymach. An EGFR mutation signature is prognostic in EGFR wild-type lung
adenocarcinomas and identifies MACC1 as an EGFR mutant-associated regulator of
MET (submitted).
Zhanga Y, R Caladob, AK Meekerc, M Raoa, JA Hong, S Ataya, P Mccormick, SH
Garfield, D Wangj, H Padilla-Nash, M Zhang, TF Kunst, NR Peterson, F Liu, S Xia, S
Inchauste, NK Altorki, AG Casson, DG Beer, CC Harris, T Ried, NS Young, DS
Schrump. A Non-synonymous Telomerase Variant Identified in Esophageal Carcinomas
Facilitates Telomere Shortening and Inhibits Non-Canonical Telomerase Activity in
Cancer Cells (submitted).
David G. Beer, Ph.D.
2/9/16
35
186.
187.
Ramnath N, CK Jeon, Colancino J, Rozedk LS, Christensen PJ, Beer DG, SH Kim.
Epigenetic regulation of Vitamin D 24-hydroxlyase (CYP24A1) in human lung
adenocarcinoma. (submitted).
Zhang Z, H Shiratsuchi, J Lin, G Chen, RM Reddy, AC Chang, DM Simeone, MS Wicha,
DG Beer, N Ramnath, S Nagrath.Isolation and ex-vivo expansion of circulating tumor
cells in early lung cancer using an in-situ organotypic microfluidic co-culture
model.(submitted).
Book Chapters
1.
Pitot HC, Beer DG, Hendrich S: Multi-stage carcinogenesis of the rat hepatocyte.
Banbury Report 25: 41-53, 1987.
2.
Pitot HC, Beer DG, Hendrich S: Multi-stage carcinogenesis: the phenomenon underlying
the theories. In: Iversson, O. (ed). Theories of Carcinogenesis. (Hemisphere Publishing
Co., New York, 158-177, 1988.
3.
Hanash SM, Richardson B, Kuick R, Wimmer K, Thoraval DH, Lamb B, Nambu Y and
Beer DG. DNA methylation changes in lung cancer. Clinical and Biological Basis of
Lung Cancer Prevention, (Y. Martinet, F.R. Hirsch, N. Martinet, J.-M. Vignaud and J.L.
Mulshine eds.) Birkhauser Verlag, Basel Switzerland, pp 157-167, 1997.
4.
Hanash SH, Richardson B, Beer DG. Relevance of DNA methylation to lung cancer. In:
Lung tumors: Fundamental Biology and Clinical Management, Brambilla, Brambilla
(eds.) New York: Marcel Dekker, Inc., Vol 124, pp227-235, 1999.
5.
Beer DG, Stoner GD. In: Clinics. Clinical models of chemoprevention: The esophagus.
W.B. Saunders Company, Philadelphia, Pennsylvania, Vol 12, (5), pp. 1055-1077, 1998.
6.
Nambu Y, and Beer DG. In: Lung Cancer, Methods in Molecular Medicine, Humana
Press, USA, “Altered surface markers in lung cancer: Lack of cell surface Fas/APO-1
expression in pulmonary adenocarcinoma may allow escape from immune surveillance:
74: 259-266, 2003.
7.
Beer DG. Molecular Prognostication of Lung Cancer, Lippincott Williams & Wilkins, HI
Pass, DP Carbone, DH Johnson, JD Minna, AT Turrisi eds. pp 270-280, 2005.
8.
Beer DG. Gene Expression Analyzes of Lung Cancer: Clinical Challenges and
Opportunities. Methods of Microarray Data Analysis III, Johnson, Kimberly F.; Lin,
Simon M. (Eds.) 2004.
9.
Chen G, Beer DG. Protein Expression Analysis. In CRC Press, “Informatics in
Proteomics” Sudhir Sirvastava ed., pp 227-254, 2005.
10.
Pass HI, Beer DG, Joseph S, Massion P. Biomarkers and molecular testing for
early detection, diagnosis, and therapeutic prediction of lung cancer. Thorac
Surg Clin. 2013 May;23(2):211-24. doi: 10.1016/j.thorsurg.2013.01.002. Epub 2013 Feb
15. PubMed PMID: 23566973.
Abstracts
1.
Beer DG, Babler M, Papaioannou S, Rapoza N: Plasminogen activator from
WI-38
cell cultures. The Pharmacologist 17: 21, 1977.
2.
Yang P, Beer DG, Papaioannou S: The binding of angiotensin II analogs to rat adrenal
David G. Beer, Ph.D.
2/9/16
36
plasma membrane and glomerulosa cells as compared to the stimulation or inhibition of
aldosterone biosynthesis. The Endocrine Society 102:83, 1978.
3.
Hjelle JJ, Grubbs JH, Beer DG, Petersen DR: Inhibition of rat liver aldehyde
dehydrogenase by carbontetrachloride. The Toxicologist 2: 135, 1982.
4.
Beer DG: Autoradiographic demonstration of specific binding and nuclear localization
of 3H-dexamethasone during normal and neoplastic lung development. Proc Amer Soc
Cancer Res. 24: 179, 1983.
5.
Beer DG, Malkinson AM: Autoradiographic localization of 3H- dexamethasone in
lung. The Pharmacologist 25: 107, 1983.
6.
Beer DG, Schwarz M, Sawada N, Pitot HC: Oncogene expression in gammaglutamyl transpeptidase positive hepatocytes isolated during the early stages
of
hepatocarcinogenesis. Terry Fox Research Conference Proceedings 54, 1985.
7.
fetoprotein and actin mRNAs in preneoplastic and neoplastic foci by in situ
hybridization. 14th International Cancer Congress, 1986.
8.
Beer DG, Coloma J, Schwarz M, Sawada N, Pitot HC: Protooncogene expression in
isolated gamma-glutamyl transpeptidase-positive hepatocytes. Proc Amer Soc Cancer
Res. 27: 79, 1986.
9.
Beer DG, Neveu MJ, Paul DL, Pitot HC: Increased expression of the c-raf
protooncogene mRNA and decreased expression of the gap junction protein
and its
mRNA in preneoplastic and neoplastic rat liver lesions. Proc Amer Soc Cancer Res 28:
146, 1987.
10.
Beer DG, Sattler C: Proto-oncogene expression in urethan-induced mouse lung
adenomas. Proc Amer Soc Cancer Res 29: 140, 1988.
11.
Nuzum E, Howell A, Droms K, Malkinson A, Beer DG: Structure and expression of the
glucocorticoid receptor gene in urethan-induced lung tumors. Proc Amer Soc Cancer Res
30: 308, 1989.
12.
Nuzum EO, Beer DG: Activation and expression of the c-K-ras oncogene in urethaninduced mouse lung tumors and tumor-derived cell lines. The Toxicologist 10: 27, 1990.
13.
Nuzum EO, Malkinson A, Beer DG: Expression of wildtype and activated Kras
alleles in mouse lung tumors. Proc Amer Soc Cancer Res. 31:310, 1990.
14.
Stahl BU, Beer DG, Rozman K: Decreased hepatic phosphoenolpyruvate carboxykinase
messenger ribonucleic acid (PEPCK-mRNA) after 2,3,7,8-tetrachlorodibenzo-P-dioxin
(TCDD) treatment in the rat. Proc Eurotox Congress p.129, 1991.
15.
Stahl BU, Beer DG, Lebofsky M, Rozman K: Decoupling of phosphoenolypyruvate
carboxykinase gene expression from its physiological stimuli after 2,3,7,8tetrachlorodibenzo-P-dioxin treatment in the male Sprague-Dawley rat. The Toxicologist
12:196, 1992.
16.
Beer DG, Hanson LA, Nuzum EO, Jones BC: K-ras mRNA overexpression in
transformed mouse lung cells can cccur by two separate mechanisms. Proc Amer Soc
Cancer Res. 33:365, 1992.
17.
Li J, Beer DG: K-ras mRNA regulation in nontransformed mouse lung cells.
Proc
Amer Soc Cancer Res. 34:519, 1993.
18.
Whyte RI, Bongiorno P, Lesser E, Moore J, Orringer M, Beer DG: Molecular markers of
poor prognosis in adenocarcinomas of the lung define unique groups of patients. Amer
Assoc Thoracic Surgeons, p132, 1993.
David G. Beer, Ph.D.
2/9/16
37
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
Wu GD, Beer DG, Moore JH, Orringer MB, Appelman HD, Traber PG: Sucraseisomaltase gene expression in Barrett’s esophagus and adenocarcinoma. Soc
Gastroenterology (accepted for Plenary Session presentation), 1993.
Li J, and Beer DG: Transfection of glucocorticoid receptor gene into transformed mouse
lung cells containing an activated K-ras allele. Proc Amer Soc Cancer Res. 35:152, 1994.
Xia Lo, Stoll SW, Hardas BD, Liebert M, Grossman HB, Carroll W, Esclamado R, Beer
DG, Nelso BR, Johnson TM, Elder JT. Loss of Can19 expression is a common event
during epithelial tumor progression in-vivo. J. Invest. Derm. 102 (4): 652-652,1994.
Xia Lo, Liebert M, Grossman HB, Beer DG, Carey TE, Elder JT. Can19 expression is
selectively reduced in epithelial tumor-derived cell lines of diverse origin. J. Invest.
Derm. 102 (4): 652-652,1994.
Li J, Johnson, TA and Beer DG: Suppression of glucocorticoid-induced growth inhibition
by AP-1. Proc Amer Soc Cancer Res. 36:262, 1995.
Beer, DG, Morse MA, Orringer MB. Metabolism and DNA binding of Benzo(a)pyrene in
Barrett's metaplasia. Proc Amer Soc Cancer Res. 37:128, 1996.
Thoraval D, Beer D, Asakawa J, Wimmer K, Kuick R, Lamb B, Law D, Hanash S.
Genomic alterations in esophageal adenocarcinoma. HUGO Human Genome Meeting,
98, 1996.
Moy J, Orringer MB, Beer DG. Gene amplification in esophageal adenocarcinoma. Proc
Amer Soc Cancer Res. 39:132, 1998.
Chang CL, Melhem RF, Beer DG, Kuick R, Hinderer R, Hanash SM. Q18E mutation of
Op18 detected in a gastric cardia tumor inhibits cell differentiation. Gastroenterology 114
(4): G2359 Part 2 Suppl. S 1998.
Lin L, Glover TW, Hanash S, Orringer MB, Beer DG. Characterization of an amplicon
on 8p22-23 demonstrating regional amplification in esophageal adenocarcinoma. Proc
Amer Soc Cancer Res. 40:542, 1999. (AACR-Genetics Institute Young Investigator
Award)
Ravikant N, Thoraval D, Zhu Z, Lamb B, Glover TW, Hanash S, Orringer MB, Beer DG.
Identification of gene amplification in esophageal adenocarcinoma using 2D genomic
scanning. Proc Amer Soc Cancer Res. 40:321, 1999.
Kresty LA, Stoner GD, Normolle D, Beer DG, Appelman H, Eaton T, Fromkes J,
Sundaram U, Moselely R, Spechler S, Habib S, Nostrant T, Jewell S. Analysis of Ki-67
and p53 in patients with non-dysplastic intestinal-type Barrett’s esophagus. Proc Amer
Soc Cancer Res. 41:223, 2000.
Joe AK, Pinto J, Beer DG, Piazza GA, Thompson WJ, Weinstein IB. Sulidac compounds
inhibit growth, induce apoptosis, and enhance glutathione synthesis in Barrett’s-derived
cancer cells. Proc Amer Soc Cancer Res. 41:494, 2000.
Lin L, Prescott MS, Orringer MB, Kuick RD, Hanash S, Glover TW, Beer DG.
Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas
using 2D genomic scanning and STS-amplification mapping.Proc Amer Soc Cancer Res.
41:725, 2000.
Aggarwal S, Taneja N, Lin L, Iannettoni MD, Orringer MB, Rehemtulla A, Beer DG.
Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves
upregulation of Bax and activation of caspase 9 independent of Cox-2 expression. Proc
Amer Soc Cancer Res. 41:825, 2000.
David G. Beer, Ph.D.
2/9/16
38
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of
cyclooxygenase-2 induces apoptosis in human esophageal adenocarcinoma cells. Proc
Amer Soc Cancer Res. 41:812, 2000.
Lord RV, Kawakami K, Brabender J, Danenberg K, Beer DG, Krasna MJ, Tamura G,
Fleisher AS, Laird PW, Eads, CA, Danenberg PV, Meltzer SJ. The presence of APC gene
hypermethylation in the serum is a specific marker for esophageal adenocarcinoma. Proc
Amer Soc Cancer Res. 41:812, 2000.
Joe AK, Liu H, Vural ME, Xiao D, Beer DG, Ting W, Weinstein IB. Resveratrol inhibits
growth, induces arrest at the S/G2 transition and apoptosis in several human cancer cell
lines. Proc Amer Soc Cancer Res. 42:19, 2001.
Lin L, Prescott MS, Orringer MB, van Dekken H, Misek D, Hanash S , Glover TW, Beer
DG. Identification and fine-mapping the core amplified domain of a 3q26 amplicon in
primary esophageal and lung cancers. Proc Amer Soc Cancer Res. 42:193, 2001.
Kresty LA, Stoner GD, Normolle D, Beer DG, Appelman H, Eaton T, Rustigi A,
Moselely R, Spechler S, Nostrant T, Fromkes J, Sundaram U, Habib S, Jewell S, Hawk
E, Brenner D. Analysis of cyclin D1 and EGFR in Barrett’s esophagus patients. Proc
Amer Soc Cancer Res. 42:867, 2001.
Arlt MF, Beer DG, Glover TW Multiple fragile sites are deleted in cancer cells.
Am. J Human Gen 69 (4): 441 Suppl. 1 2001.
Levin AM, Beer DG, Taylor JMG, Kuick R, Giordano TJ, Hanash S, Kardia SLR. Stage
III gene expression profiles identify a poor prognosis subgroup of stage I lung
adenocarcinomas.Am J Human Gen 69 (4): 476 Suppl. 2001.
Ding I, Liu W, Hu D, Fenton B, Beer D, Okunieff. Celecoxib inhibits radiation induced
angiogenic growth factor and cytokine mRNA expression in esophageal carcinoma. Proc
Amer Soc Cancer Res. 43:483, 2002.
Brenner D, Normolle D, Kresty LA, Habib S, Beer DG, Eaton T, Rustigi A, Moselely R,
Fromkes J, Spechler S, Hawk E, Appelman H, Stoner GD. Effect of
difluoromethylornithine (DFMO) upon cellular proliferation and cyclin D expression in
human metaplastic Barrett’s esophagus mucosa. Proc Amer Soc Cancer Res. 43:1007,
2002.
Beer D. Developing risk indices for identifying high-risk stage I lung cancer patients.
NCI-EORTC, 17-S2, pS19, 2002.
Lin L, Miller CT, Contreras JI, Prescott MS, Yee J, Orringer MB, Misek DE, Hanash
SM, Glover TW, Beer DG. The Hepatocyte Nuclear Factor 3 Alpha FOXA1 (HNF3)
gene on chromosome band 14q13 is amplified and overexpressed in esophageal and lung
adenocarcinomas. Proc Amer Soc Cancer Res. 43:285, 2002.
Chen, G, Gharib TG, Prescott M, Huang CC, Sheddon K,Taylor JMG, Giordano TJ,
Thomas DG, Kuick R, Iannettonni MD, Orringer MB, Hanash S, Beer DG. Protein
expression profiles predict patient survival in stage I lung adenocarcinoma. Proc Amer
Soc Cancer Res. 43:714, 2002.
Brenner D, Normolle D, Kresty LA, Habib S, Beer DG, Eaton T, Wild B, Rustigi A,
Moselely R, Fromkes J, Spechler S, Hawk E, Appelman H, Stoner GD. Effect of
difluoromethylornithine (DFMO) upon polyamine content in human metaplastic Barrett’s
esophagus mucosa. Proc Amer Soc Cancer Res. 43:1146, 2002.
David G. Beer, Ph.D.
2/9/16
39
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
Moore TC, Jepeal LI, Boylan MO, Boyd N, Beer DG, Wolfe MM Functional gastrin
receptors are present on adenocarcinoma cells of esophageal origin. Gastroenterology
122 (4): 538 Suppl. 1 2002.
Chen, G, Gharib TG, Thomas DG, Huang CC, Misek DE, Giordano TJ, Iannettonni MD,
Orringer MB, Hanash S, Beer DG. Proteomic analysis of Op-18 and elf-5A in lung
adenocarcinomas. Proc Amer Soc Cancer Res. 44:322, 2003.
Lin J, Thomas DG, Giordano TJ, Robinson GS, Barve RA, Orringer MB, Beer DG.
Melanoma-associated antigens 3 and 10: Potential targets for immunotherapy in Barrett’s
adenocarcinoma. Proc Amer Soc Cancer Res. 44:421, 2003.
Lin L Miller CT, Aggarwal S, Lin TK, Contreras JI, Dagenais SL, Orringer MB, Glover
TW, Beer DG. Amplification and overexpression of the dual-specificity Yak-related
kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas. Proc Amer Soc
Cancer Res. 44:744, 2003.
Lin J, Raoof DA, Thomas DG, Greenson JK, Giordano T, Robinson GS, Barve RA,
Orringer MB, Beer DG. L-type amino acid transporter-1 overexpression mediates uptake
of melphalan in Barrett's adenocarcinoma J.Am. Col Surg. 197 (3): S10-S11 Suppl.,
2003.
Koley H, Shammas M, Munshi N, Beer DG, Goyal R Telomerase as a therapeutic target
for Barrett's associated esophageal adenocarcinoma. Gastroenterology 124 (4): A636A636 Suppl. S 2003.
Lin L, Wang Z, Prescott MS, Albertson DG, van Dekken H, Orringer MB, Glover TW,
Thomas DG, Giordano TJ, Beer DG. Regional microsatellite instability precedes allelic
amplification in chromosomal band 3q26.3-q27 in the development of Barrett’s
adenocarcinomas. Proc. Am Assoc Cancer Res., 2004.
Misek DE, Veenstra C, Hinderer R, Giordano TJ, Beer DG, Hanash SM. Proteomics
based idnetification of tumor antigens that induce antibody response in esophageal
cancer. Proc. Am Assoc Cancer Res., 2004.
Chen G, Wang H, Miller CT, Thomas DG, Gharig TG, Misek DE, Giordano TJ, Orringer
MB, Hanash SM, Beer DG. Reduced selenium-binding protein 1 expression is associated
with poor outcome in lung adenocarcinomas. Proc. Am Assoc Cancer Res., 2004.
Raponi M, Yu J, Zhang Y, Chen G, Wang Y, Beer DG. Gene Expression Signatures of
Lung Squamous Cell Carcinomas. Proc. Am Assoc Cancer Res., 2005.
Miller CT, Lin L, Casper AM, Lim J, Thomas DG, Orringer MB, Chang A, Giordano TJ,
Glover TW, Beer DG., Mapping of genomic amplification boundaries of the MET
oncogene within fragile site FRA7G and up-regulation of MET signaling pathways in
esophageal adenocarcinoma. Proc. Am Assoc Cancer Res., 2005.
Kambhampati S, Ray G, Saxena N, Banerjee S, Sengupta K, Mehta S, Dhar A, Sharma,
Van Veldhuizen PJ, Beer DG,. Banerjee SK. Antitumor role of 2-Methoxyestradiol in
Barrett's Adenocarcinoma. Proc. Am Assoc Cancer Res., 2005.
Guoan Chen, Xiaoju Wang, Jianjun Yu, Sooryanarayana Varambally, Dafydd G.
Thomas, Thomas J. Giordano, Andrew C. Chang, Arul M. Chinnaiyan, David G.Beer
Humoral immune response profiles associated with diagnosis and prognosis in lung
adenocarcinomas. Proc. Am Assoc Cancer Res., 2005.
Maureen Baird, Samuel K. Kulp, Ching-Shih Chen, David G. Beer Roudabeh J. Jamasbi,
Qiang Lu, Laura A. Kresty. A novel histone deacetylase inhibitor, HDAC-42, induces
David G. Beer, Ph.D.
2/9/16
40
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
apoptosis, inhibits proliferation and arrests growth of esophageal cancer cells. Proc. Am
Assoc Cancer Res., 2005.
Kevin K. Dobbin, David G.Beer, Matthew Meyerson, Timothy J. Yeatman, William L.
Gerald, James W. Jacobson, Barbara Conley, Kenneth H. Buetow, Mervi Heiskanen,
Richard M. Simon, John D. Minna, Luc Girard, David E. Misek, Jeremy M. G. Taylor,
Samir Hanash, Katsuhiko Naoki, D. Neil Hayes, Christine Ladd-Acosta, Steven A.
Enkemann, Agnes Viale, Thomas J. Giordano. Inter-laboratory comparability study of
cancer gene expression analysis using oligonucleotide microarrays. Proc. Am Assoc
Cancer Res., 2005.
Xiaoying Fu, David G. Beer, Jack Wands, Jose Behar, Weibiao Cao. Role of NADPH
oxidase NOX5 in the development of Barrett’s adenocarcinoma cells. Proc. Am Assoc
Cancer Res., 2005.
Luc Girard, Chi-Leung Lam, Hisayuki Shigematsu, Maria Pik Wong, Michael Peyton,
Shelley Sheridan, David G. Beer, Adi F. Gazdar, John D. Minna. Gene profiling of lung
cancers with EGFR mutations. Proc. Am Assoc Cancer Res., 2005.
Xiaoying Fu, David G. Beer, Jack Wands, Jose Behar, Weibiao Cao Cyclic AMP
response element binding (CREB) protein is responsible for acid-induced expression of
NADPH oxidase NOX5 (short) in Barrett's adenocarcinoma cells.Gastroenterology 128
(4): A131-A132 Suppl. 2, APR 2005.
Younes, M, Rahmani M, Georgakis GG, Beer DG, Younes A. Tamoxifen induces
apoptosis in estrogen receptor-beta-positive human esophageal adenocarcinoma cells
Gastroenterology 128 (4): A602-A602 Suppl. 2, APR 2005.
Fu X, Beer DG, Wands J, Behar J, Cao W. NADPH oxidase NOX5 contributes to
increased proliferation and decreased apoptosis in Barrett's adenocarcinoma cells
Gastroenterology. 128 (4): A601-A601 Suppl. 2, APR 2005.
Fu X, Beer D, Wands J, Behar J, Cao W. Role of NADPH oxidase NOX5 in the
development of Barrett’s adenocarcinoma. Proc AM Assoc Cancer Res, 2005 46
(4):1127.
Beer DG. Expression profiling of lung cancer and it’s clinical significance. Lung Cancer
49:S14-S15, Suppl. 3, 2005.
Younes, M, Rahmani M, Georgakis GG, Beer DG, Albert VR, Younes A Functional
expression of trail receptors trail-R1 and trail-R2 in esophageal adenocarcinoma.
Gastroenterology 128 (4): A646-A646 Suppl. 2 APR 2005.
Fu X, Behar J, Eid R, Beer D, Wands J, Cao W. NADPH oxidase NOX5S (short)
mediates platelet activating factor (PAF)-induced H2O2 production in Barrett’s
adenocarcinoma cells. Gastroenterology 2006:130(4): A566.
Fu X, Behar J, Beer D, Wands J, Lambeth D, Cao W. Rho kinase and ERK2 MAP kinase
contribute to acid-induced expression of NAPDH oxidase NOS5S (short) in Barrett’s
adenocarcinoma cells. Gastroenterology 2006:130(4): A563.
Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JMG, MacDonald J, Thomas D,
Moskaluk C, Wang Y, Beer DG. Gene Expression Analyses of Lung Cell for Predicting
Prognosis. Int J Molecular Medicine, Vol 18, Suppl. 1, S61, 2006.
Lin L, Lin J, Raoof D, Wang Z, Lin M, Thomas DG, Greenson GK, Giordano TJ,
Orringer MB, Chang AC, Beer DG,. Expression and effect of inhibition of the ubiquitinconjugating enzyme E2C (UBE2C) in esophageal adenocarcinoma. Proc. Am Assoc
Cancer Res., 2007.
David G. Beer, Ph.D.
2/9/16
41
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
Si J, Behar J, Wands J, Fu X, Beer DG, Lambeth D, Chin E, Cao W. STAT5 mediates
platelet activating factor (PAF)-induced H2O2 production in Barrett’s adenocarcinoma
cells. Gastroenterology 2007.
Si J, Fu X, Behar J, Wands J, Beer DG, Spechler SJ, Souza D, Lambeth D, Cao W.
NAPDH oxidase NOS5S mediates acid-induced COX2 expression in production in
Barrett’s adenocarcinoma cells. Gastroenterology 2007.
Si J, Behar J, Wands J, Beer DG, Lambeth D, Cao W. Bile acid induced NADPH oxidase
NOX5S expression in Barrett’s adenocarcinoma cells. Gastroenterology 2007.
Lam DC, Girard L, Chau WS, et al.Gene expression signatures associated with lung
adenocarcinomas in female non-smoker Chinese patients. J. Thor Oncol 2 (8): S378-S378
Suppl. S Aug 2007.
Beer DG. Genomics and proteomics in lung cancer J. Thor Oncol 2 (8): S277-S278
Suppl. S Aug 2007.
Varker KA, Baird ME, Kulp SK, et al. A novel phenylbutyrate-derived histone
deacetylase inhibitor, S-HDACi-42, mediates acid-associated gene expression changes in
Barrett's esophageal adenocarcinoma cells. Annals of Surg Oncol 14 (2): 77-77 Suppl. S
FEB 2007.
Silvers A, Lin L, Wang Z, Chen G, Thomas D, Giordano T, Orringer MB, Beer DG,
Chang AC. Selenium Binding Protein 1 expression is decreased during esophageal
adenocarcinoma development and potentiates selenium-mediated cisplatinum
chemosensitivity in vitro. Proc AM Assoc Cancer Res, 2008.
Lin L, Wang Z, Bass A, Lockwood W, Chang AC, orringer MB, Lam WL, Meyerson M,
Beer DG. Identification of a novel amplicon on chromosome 18q11 in esophageal
adenocarcinoma. Proc AM Assoc Cancer Res, 2008.
A Qazi, CS Bryant, SKumar, M Prasad, CP Steffes, DG. Beer, RK Goyal, DW Weaver,
RB Batchu, and MA Shammas. Sulforaphane, an antioxidant derived from Broccoli,
induces apoptotic cell death in Barrett’s esophageal adenocarcinoma cells. Presented at
Digestive Disease Week meeting, held in May 2008 in San Diego, CA (Abstract
published in April 2008 issue of Gastroenterology).
MA Shammas, A Qazi, RB Batchu, RC Bertheau, JYY Wong, MY Rao, M Prasad, S
Ponnazhagan, D Chanda, CP Steffes, NC Munshi, I De Vivo, DG. Beer, S Gryaznov,
DW Weaver, & RK Goyal. Impact of Telomerase Inhibition In Barrett’s Esophageal
Adenocarcinoma (BEAC). Presented at Digestive Disease Week meeting, held in May
2008 in San Diego, CA (Abstract published in April 2008 issue of Gastroenterology).
KA. Hassan, G Chen, GP Kalemkerian, M Wicha, DG. Beer. An embryonic stem celllike gene expression signature identifies a poorly differentiated phenotype in lung
adenocarcinoma. Proc AM Assoc Cancer Res, 2009.
AL Silvers, L Lin, G Chen, Z Wang, MB Orringer, DG Beer, AC. Chang. Epigenetic and
post-transcriptional regulation decreases Selenium Binding Protein 1 (SELENBP1)
expression in esophageal adenocarcinoma. Proc AM Assoc Cancer Res, 2009.
P Saintigny, L Zhang, LGirard, Y H. Fan, JJ Lee, RS Herbst, ES Kim, K Coombes, G
Blumenschein, A Tsao, DC Lam, WL Gerald, DG Beer, XM Tang, SM Lippman, L Mao,
WK Hong, I Wistuba, JD Minna, JV Heymach. Development and testing of a mRNA
expression signature correlated with the presence of EGFR mutations in non-small cell
lung cancer. IASLC-AACR meeting, Feb 2010.
David G. Beer, Ph.D.
2/9/16
42
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, Beer D, Kalemkerian GP, and
Wicha M. Notch pathway activity identifies functional lung cancer stem cells and
correlates with worse survival in patients with lung adenocarcinoma. American
Association for Cancer Research. Abstract #496, Poster presentation, April 2011.
Zhuwen Wang, Dafydd G. Thomas, Mark B. Orringer, David G. Beer, Jules Lin.
Significance of Dickkopf-3 overexpression in the pathogenesis of esophageal
adenocarcinoma. Proc AACR 52: (#1425), 2011.
Lin L, Bass, AJ, Lockwood, WW, Wang, Z, Silvers AL, Thomas, DG, Chang AC, Lin, J,
Orringer, MB, Li, W, Glover, TW, Giordano, TJ, Lam, WL, Meyerson, ML, Beer, DG.
Amplification and activation of GATA6 sustain oncogenic lineage-survival in esophageal
adenocarcinoma. Proc AACR 53: (#2966), 2012.
S Xi, S Inchauste, Z Xiao, J Shan, M Zhang, JA Hong, MT Raiji, DG Beer, DS
Schrump.Epigenetic repression of miR-217 contributes to tobacco-induced esophageal
carcinogenesis Proc AACR 54: (#3071), 2013.
Wang Z, L Lin, DG Thomas, MB Orringer, AC Chang, DG Beer, J Lin.Overexpression
of CTGF is associated with chemoresistance in esophageal adenocarcinoma. Proc AACR
54: (#3379), 2013.
Wang Z, K Leverenz, DG Thomas, AL Myers, AC Chang, MB Orringer, TJ Giordano,
DG Beer,L Lin.Osteopontin (SPP1/OPN) alternative splice variants and metastatic
potential in esophageal adenocarcinoma. Proc AACR 54: (#3879), 2013.
Girard L, M Peyton, I Wistuba, Y Xie, R Greer, MB Suraokar, C Behrens, G Xiao, J
Heymach, DA Wheeler, CF Davis, K Huffman, D Shames, KR Coombes, AF Gazdar, D
CL Lam, DG Beer, JD Minna Molecular signatures of in vitro drug response in lung
cancer Proc AACR 54: (# 5589), 2013.
Hirsch FR, Bueno R, Tsao M, Beer D, Harpole D, Mascaux C, Wynes MW, Franklin W,
Shepherd F, Gandara D, Govindan R, on behalf of SPECS investigators. 2012. The
Squamous Lung Cancer Consortium- The Strategic Partnering to Evaluate Cancer
Signatures Program. Oral presentation at the SPORE - Lung Cancer Summer Workshop.
Hirsch FR, Bueno R, Tsao M, Beer D, Harpole D, Wynes MW, Franklin W, Shepherd F,
Gandara D, Govindan R, on behalf of SPECS investigators. 2013. The Squamous Lung
Cancer Consortium- The Strategic Partnering to Evaluate Cancer Signatures Program.
Oral presentation at the 6th International Workshop on Molecular Targeted Therapy in
Lung Cancer.
Grabauskiene S, E. Bergeron, MA Morgan, DG Beer, RM Reddy. Chk1 Protein
Expression Indicates Sensitivity to Chk1 Inhibition by Antimetabolite Chemotherapy in
Non-Small Cell Lung Cancer. Journal of Surgical Research, Volume 179, Issue 2, Pages
313-314, February 2013.
Lin J, Z Wang, DG Thomas, MB Orringer, AC Chang, DG Beer. Inhibition of CTGF
Decreases Matrigel Invasion in Esophageal Adenocarcinoma. The Journal of Surgical
Research, February 2013 (volume 179 issue 2 Page 186 DOI: 10.1016/j.jss.2012.10.072)
David G. Beer, Ph.D.
2/9/16
43